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Transplant rejection and autoimmunity are characterized by adverse inflammatory 
reactions and the absence of immuno-regulatory mechanisms. One of the most common 
treatments for these conditions is the use of immunosuppressive agents that non-specifically 
suppress immune cell function. However, these agents are associated with many drawbacks that 
include renal and hepatic toxicities as well as increased risk of infections and malignancies. A 
promising alternative to immunosuppressants is the utilization of the immune system’s natural 
regulatory mechanisms. Cellular therapies, comprising of tolerogenic dendritic cells (tDC) and 
regulatory T cells (Treg), which exploit these regulatory mechanisms are currently under 
development. Unfortunately, therapies that use tDC and Treg are associated with many 
challenges such as; difficulty in isolating these cells, problems in maintaining their regulatory 
phenotype under ex vivo culture conditions, and the prohibitive infrastructure requirements in 
culturing these cells under ‘GMP’ conditions. A potential solution to these problems is the 
development of prospective therapeutics that would alter regulatory cell numbers and function in 
vivo. To this end, we developed three new degradable and biocompatible formulations to 
modulate regulatory immune responses.  The first formulation involves the encapsulation of an 
immusuppressant, rapamycin, into appropriately-sized microparticles (rapaMP) that can 
specifically be targeted to phagocytic cells in vivo. RapaMP-treated DC show lowered 
expression of co-stimulatory markers and decreased ability to stimulate T cell proliferation, both 
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of which are suggestive of their capacity to suppress immune responses in vivo. The second 
formulation involves the encapsulation of a chemokine capable of Treg recruitment (CCL22) 
into sustained release vehicles (CCL22MP). Our data demonstrates that CCL22MP are able to 
recruit Treg in vivo, and show promise in delaying cell and composite tissue graft rejection. The 
third formulation involves the encapsulation of factors (IL-2, TGF-β and rapa; FactorMP) that 
we have identified as agents capable of Treg induction. We show that FactorMP are capable of 
inducing functional Treg populations from both mouse and human cells, and could possibly 
create a local immunosuppressive environment in vivo that favors Treg proliferation. Controlled 
release formulations such as these, could potentially be developed as “off-the-shelf” therapeutics 
for the treatment of transplant rejection and autoimmunity. 
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1.0  INTRODUCTION 
Transplantation refers to the procedure of transferring cells and tissues from one location in the 
body to another (auto-transplantation) or from one body (donor) to another (host).  This donor 
tissue may be of human (allo-transplantation) or non-human (xeno-transplantation) origin. The 
process of transplantation has been practiced for centuries, with some of the earliest reports 
dating as far back as 600 B.C. when the Indian surgeon Sushruta performed skin auto-
transplantation for facial reconstruction [1]. Over the past few decades, allo-transplantation of 
solid internal organs has become common due to the advent of modern immunosuppressive 
drugs and improved surgical techniques [2]. Examples of some of the most commonly 
transplanted solid organs include kidneys, liver, lung and heart. The scientific registry of solid 
organ transplant recipients estimates that, at present, over 100,000 patients are living with a 
functioning transplant in the USA, and each year around 20,000-30,000 patients are added to this 
list [3]. Although the field of solid organ transplantation has grown considerably, it is still 
plagued with the problem of “rejection”. Rejection is the response of the host’s immune system 
against a donor allo-transplant, which is naturally recognized as foreign/non-self tissue [2, 4]. To 
understand the concepts of transplant rejection, one must first learn how the immune system 
works. The next section briefly describes the immune system and its components. 
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1.1 THE IMMUNE SYSTEM 
A tremendous number of parasites and other infectious agents constantly threaten to invade and 
cause harm to organisms such as humans. Preventing the entry, proliferation and colonization of 
these pathogenic organisms is by no means a simple task. For this reason, the mammalian body 
has developed a complex immune system for defending itself from such infections.  The primary 
goal of this system is to kill or sequester any foreign agent that enters the body, and also prevent 
proliferation and spread of abnormal self tissue (tumors) [5]. The integumentary system (skin, 
nails etc.) and the epithelial lining of the respiratory and digestive systems passively assist the 
immune system in preventing the entry of pathogens, while a number of cellular and acellular 
components of the immune system actively take part in neutralizing the agents that have made it 
past the initial entry barrier. The major components of the immune system can broadly be 
divided into the innate immune system and the adaptive immune system. 
1.1.1 Innate Immune System: 
Upon successful entry through the passive barriers, infectious agents first encounter the 
components of the innate system.  For this reason, the innate immune system is often referred to 
as the first active line of defense. The cells of this system distinguish pathogen-associated 
cellular material from self tissue using a variety of discriminating features that can broadly be 
defined as pathogen or danger associated molecular patterns (PAMPs and DAMPs) [5-6]. 
Following identification of a pathogen, the innate immune system establishes a cascade of 
responses which are briefly described below (detailed description of this process can be found in 
reference [5]).  
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Tissue resident macrophages are the first cells of the immune system that encounter the 
invading pathogen. Macrophages as their name suggests, are phagocytic cells that are capable of 
ingesting entire microbes and killing (oxidizing) them in their endosomes / phagosomes. In 
addition to ingesting and neutralizing microbes, macrophages recognize PAMPs through cellular 
receptors on their surface. This recognition event leads to cellular activation and secretion of 
danger signals (cytokines and chemokines), which establish an inflammatory environment at the 
site of microbe entry. As Janeway and colleagues discuss [5], establishing an inflammatory 
environment is necessary for combating infection as; (i) it is the primary means by which 
immune cells are recruited to the site of microbe entry, and (ii) it allows for the creation of a 
physical barrier (through coagulation of blood vessels) that prevents the spread of the invading 
microbial agent. 
Circulating neutrophils respond first to these inflammatory signals. They assist 
macrophages in ingesting invading microbes, and help to augment the inflammatory response. 
Many other cells of the innate immune system, such as eosinophils, basophils and mast cells can 
also be recruited to the site of infection, depending on the type of pathogen and tissue. The 
inflammatory mediators (mainly IFN-β, TNF-α and IL-12) also help to recruit and activate 
Natural Killer (NK) cells which are important in clearing away infections caused by intracellular 
pathogens. 
Most importantly, professional antigen presenting cells known as dendritic cells (DC) 
[7] are also recruited to the site of microbial entry/infection. DC ingest “antigens” (whole 
microbes or cellular material from infectious organisms) and migrate to the lymph nodes where 
they can activate naïve T cells in an antigen-specific manner. Due to their unique capability of 
activating naïve T cells and initiating adaptive immune responses, DC are often referred to as the 
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bridge that connects the innate and the adaptive immune system. The process of DC-based T cell 
activation is very briefly described below (Figure 1) [5]. Antigens taken up by DC are digested 
inside phagosomes, and antigen fragments are presented on the cell surface attached to major 
histocompatibility (MHC) receptors. The antigen-MHC complexes bind to the T cell receptor 
(signal 1) leading to T cell activation. For strong, effective and stable activation, the DC must 
also express co-stimulatory molecules (CD80, CD83, CD86 among others), which bind to the 
CD28 receptor on the T cell surface (signal 2).  Further, DC secrete soluble mediators 
(cytokines) that promote activation and differentiation of T cells (signal 3). The activation of T 
cells is the first step towards establishing a strong adaptive immune response against the 
invading pathogen. 
 
 
 
 
Figure 1: Cartoon describing DC-T cell interaction [5]. 
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1.1.2 Adaptive Immune System: 
The adaptive immune system, as its name suggests, has the remarkable ability to “adapt” itself to 
generate antigen/pathogen specific immune responses.  The resulting highly specialized immune 
responses allow the body to fight against pathogens that have developed methods to bypass the 
innate immune system. T and B lymphocytes (as the mediators of adaptive immunity) are able to 
generate literally billions of different cell surface receptors (T cell receptors (TCR) and B cell 
receptors)  through a genetic recombination process providing a way to recognize an equally 
diverse number of antigens expressed on the surface of various pathogens [8]. Upon interaction 
with DC that display a “specific antigen” coupled to their MHC receptors, “antigen-specific” T 
and B cells clonally expand and initiate antigen-specific adaptive immune responses in order to 
neutralize the corresponding antigen-bearing pathogen. Furthermore, a key characteristic of the 
adaptive immune response is its ability to generate immunological memory. Following the 
completion of the immune response against a pathogen, a select number of activated antigen-
specific T and B cells survive to become memory cells. This “memory” allocation allows the 
body to respond to the same antigen faster than if the antigen were to be encountered anew. The 
details of this particular type of immune response will not be discussed in this dissertation (and 
can be found elsewhere [5]).  However, the cells that form the adaptive immune system are 
described briefly below. 
B and T lymphocytes are constantly generated from hematopoietic stem cells in the bone 
marrow, and there is believed to be a rapid turnover of these cells under immune homeostasis. B 
cells arise and mature in the bone marrow, where cells expressing self-reactive receptors are 
deleted. Following maturation, B cells for the most part reside in the lymphoid systems until the 
time they are activated. Upon activation these cells secrete antibodies against the specific 
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antigen, which is known as the humoral immune response. T cells in turn are also named after 
their site of maturation – the Thymus. Similar to B cells, T cells that express self-reactive 
receptors are deleted in the thymus, but differ from B cells in their function following activation. 
The two most well described and widely studied classes of T cells are: (i) helper T cells (express 
the CD4 receptor) – assist in establishing antigen specific immune responses through various 
means, such as activation of the CD8 expressing T cells, B cells, NK cells and macrophages; (ii) 
cytotoxic T cells (express the CD8 receptor) – directly take part in killing an infected cell or 
pathogen. This dissertation will mainly focus on the CD4+ T cells, especially on a subset of these 
cells that are known to regulate the immune system. 
CD4+ helper T cells can differentiate into different subsets depending upon the activating 
conditions presented by the DC (signal 3 from Figure 1) during the process of activation. 
Broadly CD4+ T cells may be characterized into 4 different classes, Th1, Th2, Th17 and 
regulatory T cells (Treg), although other minor sub-classes of cells have been reported in 
literature [9]. The phenotypical and functional characteristics of Treg will be discussed in later in 
this chapter (Section 1.10). 
The next section will briefly describe the role of innate and adaptive immune cells in 
rejecting a transplant. 
1.2 REJECTION IMMUNE RESPONSES 
The immunological nature of transplant (graft) rejection was first discovered by Medawar and 
colleagues [4, 10], although at that time it was unclear as to what components of the immune 
system played a role in these responses. Over the past 50 years, immunologists have described 
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the immunological processes involved in rejection in great detail (reviewed in [11]). The 
following section will briefly summarize some of the main components of these complex 
immune responses against an allograft. 
Transplantation surgery is associated with significant trauma as the 
diseased/dysfunctional tissue needs to be detached from the connecting blood vessels and nerves 
and new transplanted tissue reattached. This trauma acts as a “danger” signal [12] that initiates 
innate immune responses. Tissue transplantation is followed by a series of acute inflammatory 
episodes that are mainly directed by tissue resident macrophages, DC, invading neutrophils, and 
NK cells of the innate immune system [12]. Inflammatory mediators secreted by these cells can 
cause significant damage to the graft. Additionally, NK cells can take part in the killing of graft 
cells due to MHC mismatch. Further, the inflammatory environment can activate graft-associated 
antigen presenting cells (APC) to initiate a corresponding adaptive immune response. 
Adaptive immune responses against a transplant can rise from two different types of 
antigen presenting cells. During the acute rejection phase (<6 months post transplant), it is 
believed that donor derived DC [13] (cells from the graft) are the most important stimulators of 
naïve T cells. The process of donor derived DC (which express distinct MHC molecules from 
host cells) acting as primary APC is called direct antigen presentation [13]. Interestingly, it has 
been shown that a large percentage of naïve T cells (~10%) can be primed by these MHC 
mismatched DC [12]. Such large numbers of activated T cells directly take part in graft 
destruction and also enhance other immune responses against the graft. For example, CD4+ T 
cells initiate delayed type hypersensitivity responses by macrophages. Additionally, CD4+ T 
cells can also activate B cells to secrete graft-specific antibodies. Adaptive immunity can also be 
initiated by host DC that present graft associated antigen to naïve T cells, a process called 
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indirect antigen presentation [13]. The immune responses initiated by host DC have not reported 
to be different from those generated by donor DC.  However, it is believed that host DC play a 
much greater role in chronic rejection responses (>1 year post transplant) presumably following 
the destruction of all donor-derived DC [12]. 
Treating rejection has been a challenge, given the complicated nature of immune 
responses against the graft and the involvement of the many of the same cell types that actively 
protect us from infections. The next section will focus on some of the current clinical treatments 
for suppressing rejection responses.  
1.3 IMMUNOSUPPRESSIVE THERAPIES 
 
The advent of modern immunosuppressive drugs revolutionized the field of transplantation 
surgery by allowing the survival of allografts for much longer time frames [2, 11]. While a few 
decades back allografts would be rejected within a few days [4, 10], it is not uncommon today 
for allografts to survive for several years. With longer survival times, allo-transplantation has 
become more common, and patients with specific organ failures are now provided with a viable 
treatment option that did not exist in the past. This section will review some of the most 
commonly used immunosuppressive agents in chronological order of their use in the clinic. 
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1.4 IMMUNOSUPPRESSIVE AGENTS 
1.4.1 Azathioprine 
Azathioprine, introduced by Calne and colleagues, is an analog of purines (bases that are part of 
the DNA), and inhibits immune cell proliferation through its effects on purine metabolism in 
cells (reviewed in [14]). It was the first drug (chemical) that allowed for long term survival of 
transplants (up to several weeks) by effectively suppressing rejection responses and not being 
lethal over a short course of treatment [15] (reviewed in [16]). Azathioprine was commonly used 
in combination with steroids for immunosuppression before the introduction of calcineurin 
inhibitors, and even today it is commonly used in triple or quadruple therapy maintenance 
immunosuppression [17]. Due to its generic ability to suppress cell proliferation, azathioprine 
has many adverse side effects, such as the suppression of bone marrow cells leading low red 
blood cell and neutrophil counts. 
1.4.2 Corticosteroid derivatives 
Corticosteroids are naturally occurring hormones in the body with many functions, including 
modulating the immune system. Synthetic derivatives of naturally occurring corticosteroids that 
have longer half lives, greater stability and lower toxicities are some of the most potent and 
commonly used drugs for suppressing immune responses. At high doses these agents are known 
to directly cause cell lysis, but at moderate doses they can affect a range of immune cell 
functions by influencing the cytokine production machinery [17]. These drugs are commonly 
used in most immunosuppressive regimens after a transplant procedure, and are often the first 
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choice of medication for acute rejection episodes. Long term use of corticosteroid derivatives can 
lead to serious health risks, which include but are not limited to, cardiovascular problems, 
increased risk of infection and tumors, alterations in growth hormone production and severe bone 
loss. 
1.4.3 Cyclosporine 
Cyclosporine, introduced first by Calne and colleagues [18-19], dramatically altered the 
landscape of immunosuppression following solid organ transplantation by delaying rejection of 
allografts from several months to years. Such a significant change in graft survival times was due 
to the high therapeutic index (i.e. effective dosage is low and toxic dosage is high) of the drug 
that allows for continuous immunosuppression for long periods of time with limited side effects 
[17]. Cyclosporine functions by inhibiting the function of calcineurin enzymes and subsequent 
downstream signaling events. This inhibition leads to altered secretion of many inflammatory 
cytokines and increased production of immunosuppressive mediators such as TGF-β [20]. Even 
though cyclosporine has a high therapeutic index, it is known to have severe side effects 
(primarily nephrotoxicity) associated with continuous use for several years. Finally, it is unable 
to control chronic rejection responses, which eventually leads to graft rejection [17, 21]. 
1.4.4 Rapamycin 
Rapamycin (rapa; also known as sirolimus or rapamune; Figure 2) was discovered in the 1970’s 
as an antifungal agent produced by Streptomyces hygroscopicus. Upon the discovery of the 
potent immunosuppressive agent tacrolimus (a drug that is similar in structure to rapa and is 
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known to bind the same intracellular protein), rapa was reevaluated for its ability to suppress 
immune responses (reviewed in [22-23]). Rapa forms a complex with FK binding protein, and 
this complex affects the activity of the intracellular protein mammalian target of rapamycin 
(mTOR). Through this interaction, rapa affects many immune cell functions, which include 
suppression of cellular proliferation driven by cytokines and CD28 downstream signaling in T 
cells [24]. A significant advantage of rapa over other immunosuppressive drugs is its low 
systemic toxicity and negligible nephrotoxicity [25-26] (a significant problem with the most 
commonly used immunosuppressants cyclosporine and tacrolimus). Hence, rapa is now 
commonly used in immunosuppressive regimens, and is clinically approved for renal 
transplantation [25, 27-28]. Although rapa is known to have low systemic toxicity in most animal 
models, it has been shown to adversely affect gastrointestinal functions in dogs and cause 
testicular atrophy in monkeys (reviewed in [23]). Even though a few of these unwanted side 
effects have been reported in humans too, given its therapeutic potential rapa is currently used in 
the clinic.  
 
 
 
Figure 2: Structure of rapamycin 
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A noteworthy point about the immunosuppressive functions of rapa is its ability to alter 
immune cell function through mechanisms that are independent of direct cell proliferation 
suppression [29-31]. For example, rapa is known to affect DC function driving the cell towards 
a more “tolerogenic” phenotype, and has the potential to synergize with TGF-β to induce naïve T 
cell to regulatory T cell conversion [32] (discussed in greater detail in later chapters). One of the 
primary focuses of this dissertation will be to exploit the two aforementioned functions of rapa 
for the promotion of immune tolerance. 
1.4.5 Immunosuppressive antibodies 
Antibodies against immune cell receptors are commonly used to block the function of these cells 
or to deplete them through the complement or antibody dependent cell cytotoxicity pathways. 
Immunosuppressive regimens that include such antibodies are very useful as a prophylactic 
treatment before transplantation and to quickly treat acute rejection episodes (where a rapid 
depletion of immune cells and their functions, is required). Antilymphocyte antibodies currently 
in use in the clinic are mainly directed against a variety of receptors expressed on T cells. For 
example, anti-CD3 antibody (Muromonab®) was the first antibody approved for use in humans 
as a drug. It rapidly depletes all CD3 expressing T cells from circulation, thereby suppressing 
adaptive immune responses for a short time (reviewed in [33]). New CD3 expressing T cells 
arise soon after cessation of treatment with Muromonab®. Muromonab® cannot be used for long 
time-periods as repeated administration of this antibody leads to the development of neutralizing 
antibodies against anti-CD3, which reduces the efficacy of this treatment. Another antibody 
preparation, against CD52 (anti-CD52, developed by Waldmann and colleagues) [34-35], has 
been quite effective at suppressing immune responses due to its ability to deplete immune cells 
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expressing CD52 (T cells, B cells and NK cells among other immune cells). Currently, this 
antibody is used in triple and quadruple immunosuppressive regimens [36-37](reviewed in [17]). 
While effective, antilymphocyte antibodies can increase the risk of infections and tumors; hence, 
their clinical use is restricted to short treatment durations and usually only during acute rejection 
episodes. 
1.5 TOXICITY PROBLEM 
One significant disadvantage of all of the aforementioned immunosuppressive drugs is their 
toxicity to native cells of the body due to systemic administration. Most pharmaceutical 
chemicals have this problem, but the deleterious effects are greatly magnified in the case of 
immunosuppressive drugs due to the need for life-long administration of these agents. Given that 
most of these agents have similar toxicities to liver, gastrointestinal and kidney tissue, it is 
difficult to solve the toxicity problem just by altering the immunosuppressive drug administered. 
Instead, one viable alternative is to develop strategies to deliver the immunosuppressive drugs 
specifically to the transplant site instead of systemically. 
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1.6 DRUG DELIVERY APPROACHES FOR IMMUNOSUPPRESSION 
1.6.1 Introduction to Drug Delivery 
Today, it is well recognized that delivery of therapeutic agents at appropriate doses, precise time 
intervals and to specific locations in the body is necessary to observe the best possible treatment 
effect. Drug delivery formulations that achieve these goals are known to improve effectiveness 
of the therapeutic [38]. Historically, the most commonly used formulations have been pills (that 
are consumed orally) and liquids (that are injected intravenously). However, these formulations 
have two major disadvantages: (i) systemic delivery of drugs is often associated with toxicity to 
liver, kidney and gastrointestinal cells; and (ii) inability to maintain constant drug levels in the 
body leading to the presence of either toxic (high) or non-therapeutic (very low) concentrations 
in the blood. To solve the first problem, many different drug targeting strategies have been 
developed (discussed in detail in [39-40]). Although immunosuppressive drug targeting 
strategies hold tremendous promise, suppressing rejection responses using this approach remains 
difficult due to the complexity and redundancy of immune responses against a graft. Further, 
while it is relatively easy to actively target biological therapeutics (e.g. antibodies), targeting 
small molecules (e.g. immunosuppressive drugs) remains a significant challenge.   
The second problem with the use of pills and injections is the inability to maintain 
constant drug levels in the body (Figure 2A) and the need for regular and frequent consumption 
of these drug formulations, which requires a high degree of patient compliance. Sustained release 
formulations were designed to overcome these limitations (Figure 2B) [41]. Sustained release 
systems are capable of providing spatial as well as temporal control over the release of the drug. 
In these formulations, the drug is usually combined with an inert degradable polymeric material 
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that can serve as a slow-release drug depot. Upon injection or implantation in the body, the drug 
is released from the formulation based on the degradation rate of the polymer as well as passive 
diffusion kinetics of the drug through the material. The amount and rate of drug release can be 
controlled by altering the (i) quantity of drug loaded into the material, (ii) method of loading, and 
(iii) properties of the material. Some of the first such formulations were fabricated close to half-
a-century ago [42].  
One of the most important uses of sustained release formulations is the ability to 
encapsulate and controllably release biological macromolecules such as proteins and DNA. 
Biological agents have a narrow therapeutic window and very short half lives in vivo. Hence, 
their delivery through traditional pills and injections is cumbersome and expensive. In a seminal 
paper in the field of drug delivery, Langer and Folkman showed for the first time that polymer 
based formulations can be used for sustained release of biological macromolecules [43], thereby 
solving many of the problems associated with using  these macromolecules as drugs. Since then 
there have been numerous reports on the development of novel formulations for a variety of 
small molecules as well as biological agents (reviewed in [44] and [45]). 
1.6.2 Controlled release of immunosuppressive agents 
The earliest reports of sustained release formulations for immunosuppressive drugs were 
published two decades ago [46-48]. Subsequently, there have been multiple reports on the 
encapsulation and controlled release of immunosuppressive agents. For example, sustained 
release formulations for cyclophosphamide [46], dexamethasone [49-50], cyclosporine [47, 51-
53], tacrolimus [54-56], and rapamycin [57-59] have been fabricated previously. Intra-transplant 
injections of these formulations can maintain high local levels of drug while reducing systemic 
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toxicity. However, local application of controlled release vehicles is limited by the fact that 
immune responses against a graft usually arise at secondary lymphoid tissues that are distal to 
the transplant site. Sustained release formulations can also be used as depots for controlled 
release of immunosuppressive drugs (that would maintain a constant drug level in the blood). 
However, systemic toxicity still remains an issue in this case. Further, the formulations described 
above cannot overcome drawbacks that are inherent to immunosuppressive drugs, which are 
discussed in the next section. 
1.7 ALTERNATIVE APPROACHES TO IMMUNOSUPPRESSION 
Direct suppression of immune cell proliferation mediated by immunosuppressive drugs is 
associated with many side-effects [60-61], some of which have been discussed in earlier sections 
of this chapter.  Additionally, it is known that these agents are unable to prevent chronic 
rejection, and may act as a barrier to the indefinite acceptance of the transplanted tissue [62-64]. 
Importantly, these critical drawbacks are inherent to the immunosuppressive strategy employed 
by these drugs and cannot be solved by developing new drug delivery formulations (as discussed 
in the previous section). Thomson and colleagues [65-66], Dallman [12], Kaplan and colleagues 
[62] among many others have suggested that the best possible treatment for transplant rejection 
is getting the immune system to accept the transplanted tissue as self, a phenomenon that is 
termed as tolerance. The next few sections introduce the concepts of tolerance and describe 
some of the cell types that maintain immune homeostasis in the steady state and discuss their role 
in preventing transplant rejection.  
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1.8 IMMUNO-TOLERANCE AND TOLEROGENIC DENDRITIC CELLS 
1.8.1 Tolerance 
The mechanisms utilized by the immune system to defend the body from infectious agents and 
abnormal native cells are capable of damaging self-tissue. The immune system has developed 
elaborate means to prevent such collateral damage; either through inactivation of immune cells 
that act against self tissue (tolerance) or by closely regulating inflammatory responses at a 
disease site (immunoregulation that can involve tolerance inducing mechanisms) [66-67]. A key 
feature of immunological tolerance is the ability of the immune system to differentiate between 
self tissue and pathogens. Burnet and Fenner first postulated the presence of tolerance in the 
immune system - “The failure of antibody production against autologous cells demands the 
postulation of an active ability of the reticulo-endothelial cells to recognize ‘self’ pattern from 
‘not-self’ pattern in organic material taken into their substance” [68] (adapted from Baxter [69]). 
Following the postulation of this theory, research has demonstrated that the immune system 
maintains tolerance to self tissues through many different means, which can be combined into 
two broad groups – central and peripheral tolerance [70]. 
Central tolerance is the process by which the immune system deletes T and B cells that 
respond to self antigen. The process of genetic recombination that gives rise to T and B cell 
receptors with different antigen specificities does not exclude them from recognizing self-
antigen. To prevent damage to self-tissue, these T and B cells are induced to undergo apoptosis 
during the maturation process in the thymus and bone marrow, respectively [70]. However, not 
all self-reactive cells are successfully eliminated in the thymus and bone marrow through these 
processes [71-72].  
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Peripheral tolerance is the process of preventing activation and proliferation of self-
reactive cells that reach lymphoid circulation. It is chiefly maintained by two distinct cell 
populations: (i) dendritic cells (DC) that are “tolerogenic” (tolerance generating); and (ii) 
regulatory T cells (Treg). Tolerogenic DC and Treg can function together or independently.  
Also, each cell type is suspected to have the capability to induce the other for help in generating 
tolerance. The following two sections will describe tolerogenic DC and Treg, respectively.  
1.9 TOLERANCE-INDUCING DENDRITIC CELLS 
As discussed in Section 1.1, the initiation of adaptive immune responses is dependent on antigen 
presentation by DC. DC activate CD4+ T cells through MHC-TCR and co-stimulatory surface 
receptor interactions as well as soluble cytokine based signaling. These three signaling 
mechanisms, together, shape the nature of the adaptive immune response from immunity against 
pathogens to tolerance towards self-tissue. Until the turn of the century, it was unclear how DC 
could control such diverse responses. Two pioneering theories (infectious-self (proposed by 
Janeway [6]) and the danger model (proposed by Matzinger [73-74])) helped to explain the 
tremendous diversity of DC function. Janeway and Medzhitov proposed that antigen presenting 
cells (including DC) are able to identify self from infectious agents by recognizing molecular 
patterns that are specifically expressed on pathogens [6, 75-76]. Matzinger proposed that 
immune responses are initiated when an antigen is presented to the immune system in the context 
of “danger signals” [73-74]. The corollary to these ideas was that in the absence of infections or 
danger signals, presentation of antigens by DC would be considered innocuous and tolerance 
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would ensue. Subsequently, these theories have been shown to hold true by many different 
groups (reviewed in [66, 77]). 
DC are able to control immunity and induce tolerance by altering T cell activation 
signals. Modulation of signals that activate T cells can lead to multiple different outcomes, such 
as: (i) induction of T cell anergy or absence of functional activity that occurs due to MHC-
antigen presentation in the absence or under very low levels of co-stimulatory signaling using 
CD80/83/86 [78-82]; (ii) induction of tolerance by constantly presenting antigen over long time-
periods leading to T cell exhaustion (reviewed in [83]); (iii) induction of effector T cell 
apoptosis; and most importantly, (iv) establishment of dominant tolerance through induction and 
proliferation of Treg through secretion of immunosuppressive factors such as TGF-β [84-85], IL-
10 [86], prostaglandins [87], or retinoic acid [88] (reviewed in [89]). The following section 
reviews some of the most commonly used techniques to generate tolerogenic DC. 
1.9.1 Antigen presentation through immature DC 
In the native homeostatic state (absence of an infection), DC exist as immature antigen 
presenting cells that have high phagocytic capacity while expressing low levels of co-stimulatory 
receptors [90-91]. As suggested in figure 1 and by Janeway [6] and Matzinger [73-74], under 
these conditions, DC are poor activators of T cells. This natural state of DC is used by the body 
to induce and maintain tolerance against self antigen. Native proteins and apoptotic cells are 
phagocytosed readily by immature DC. This process occurs in the absence of danger signals 
(apoptotic cells and native proteins do not activate the “danger receptors (TLR)” on DC), leading 
to native antigen presentation in the absence of co-stimulation (co-stimulatory receptors have 
been shown to be upregulated only upon TLR activation [92]). Such antigen presentation in the 
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absence of co-stimulation generally leads to T cell anergy [78-79], which allows for 
establishment of tolerance against the native antigen. 
Immunologists have attempted to exploit this mechanism of generating tolerance for 
treating autoimmunity and transplant rejection. For example, Steinmann and colleagues have 
shown that targeted delivery of any antigen (a small peptide or an intact whole protein) to 
quiescent DC (using antibodies against DC receptors such as DEC-205) can induce tolerance 
towards that particular antigen [93-94] (reviewed in [91]). This approach has subsequently been 
used to suppress and prevent immune responses in murine models of diabetes [95] and 
experimental autoimmune encephalomyelitis [96]. Similarly for transplantation, researchers have 
recognized that adoptive transfer of immature allogeneic DC (DC isolated from the donor) can 
induce donor antigen-specific tolerance [78-79] (reviewed in [65]). Immature donor-specific DC 
have been shown to induce T cell anergy [78, 80] and drive Treg proliferation in vitro [97-98], as 
well as significantly prolong survival of heart [78] and islet allografts [99].  
1.9.2 Altering DC function using genetic material 
The task of reducing expression of co-stimulatory surface proteins or secretion of inflammatory 
cytokines, or increasing the production of immunosuppressive proteins to generate a tolerogenic 
DC can effectively be achieved by using silencing RNA and recombinant gene constructs 
respectively.  For example Thomson and colleagues have suggested that transfecting DC with 
recombinant genes that code for IL-10, CTLA-4, or TGF-β, among many other proteins, can be a 
potential approach to generating tolerogenic cells [65, 100-101]. However, the potential for this 
approach has not been realized due to fears over the safety of the use of genetic constructs in 
humans and difficulties in achieving high transfection efficiencies in DC. An alternative 
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approach pioneered by Giannoukakis and colleagues is the use of antisense RNA to silence gene 
products of co-stimulatory surface proteins CD40, CD80 and CD86 [102]. Their work has lead to 
the initiation of clinical trials at the University of Pittsburgh Medical Center using this 
technology [103]. 
1.9.3 Modulation using immunosuppressive pharmacological agents 
During the past two decades, numerous studies have enumerated the role of immunosuppressive 
and immunomodulatory agents in modulating DC function ex vivo and in vivo (reviewed in 
[31]).  Corticosteroids, vitamin D3 (and its metabolite 1α,25-dihydroxyvitamin D3), cyclosporine, 
tacrolimus, mycophenolate mofetil, aspirin and rapamycin (rapa) are some of 
immunosuppressive drugs that  have been shown to affect DC differentiation / maturation, 
thereby altering their function. Most of these agents negatively affect intracellular pathways 
responsible for up-regulation of co-stimulatory molecules and/or secretion of inflammatory 
cytokines, while some can positively affect immunosuppressive pathways by increasing the 
production of transforming growth factor β1 (TGF-β), IL-10 and indoleamine 2,3-dioxygenase 
(IDO). These agents can also affect the migratory capacity of DC, thereby altering their ability to 
interact with lymphocytes in vivo.  
One immunosuppressive agent that is of special interest to transplant immunologists is 
rapa, as it suppresses the ability of DC to activate effector T cell proliferation, while promoting 
Treg proliferation [32]. Rapa inhibits downstream signaling from the kinase mammalian target of 
rapamycin (mTor), which leads to impaired DC maturation and T cell stimulatory function. 
Thomson and colleagues show that rapa treatment of in vitro bone marrow derived DC, 
decreased expression of co-stimulatory molecules on the surface as well as lowered secretion of 
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IL-12 and tumor necrosis factor (TNF) [30]. Additionally, they also show that rapa-treated DC 
can be used as a cellular therapy for the prolongation [104] and promotion of indefinite survival 
of heart allografts [32]. These results hold promise for the clinical translation of rapa-conditioned 
DC as a treatment for delaying graft rejection and potentially inducing transplant tolerance. 
1.9.4 Tolerogenic DC in the clinic 
Promising results obtained from clinical trials of DC-based therapies for cancer provide support 
to the idea that a tolerogenic DC based approach can be used to promote immuno-regulation [65, 
105]. A large number of studies in small animal models (mouse and rat) have highlighted the 
efficacy of in vitro generated tolerogenic DC in promoting tolerance to transplants. For clinical 
translation of this research, an important and necessary step is to replicate the aforementioned 
studies (generating tolerogenic DC and testing for induction of tolerance) in large animal models 
(non-human primate) [65, 106]. Thomson and colleagues have been working towards generating 
tolerogenic DC in the Rhesus monkey [107-108], with the ultimate goal of optimizing protocols 
for the use of DC therapy in humans. Data from these studies will go a long way towards the 
translation of tolerance generating cellular therapies to the clinic. Further, along these lines, it is 
important to note that Giannoukakis and colleagues have started (for the first time) clinical trials 
to test the effect of using antisense RNA treated DC as a therapy for type-I diabetes [102-103]. 
This approach has the potential to be applied in promoting graft tolerance as well.  
Regardless, an important aspect to consider while developing tolerogenic DC-based 
therapies are the problems associated with ex vivo cell culture. Isolation and culture of these 
cells under GMP conditions is cumbersome, expensive and often plagued with problems of 
stability and purity of cell populations. In vivo targeting of DC with tolerance inducing agents 
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has been suggested as a potential alternative to bypass these problems [65, 101]. Candidate 
therapies under development along these lines follow the previously described techniques to 
generate tolerogenic DC: (i) DC specific antigen delivery - DEC-205 based targeting of antigens 
to immature DC in vivo [91, 95]; and (ii) altering DC function with genetic material - delivery of 
antisense-RNA using appropriately sized microparticles to phagocytic cells in vivo [102]. 
Systems for the in vivo modulation of DC function, by targeting immunosuppressive drugs to 
these cells, are yet to be developed. Given the relative safety (approved by the United States 
Food and Drug Administration) and diversity of immunosuppressive drugs, such targeted 
therapeutics might dramatically reduce the time to develop a therapy that can be used in the 
clinic. 
1.10 REGULATORY T CELLS AND IMMUNOREGULATION 
1.10.1 Historical perspective:  
Over the past couple of decades, immunologists have identified that not all self-reactive T cells 
are deleted in the thymus and that many of them are present in the lymphoid circulation [71-72]. 
The presence of self-reactive T cells in the periphery posed an interesting conundrum – why 
don’t these cells initiate immune responses against self in healthy individuals? Pioneering studies 
in the 1980’s and 90’s demonstrated that the immune system has active suppressive mechanisms 
in place to prevent self-reactivity, and that this suppression is mediated by “certain” T cells [109-
111] (reviewed in [112]). For a long time, the presence of such suppressive T cells was viewed 
with skepticism, mainly due to difficulties in identifying a standard set of specific markers that 
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allowed for isolation and study of these cells. For example, the Mason group used CD45 
isoforms to distinguish the suppressor T cells [111-112], while the Sakaguchi group used CD5 
[110]. But neither of these markers could be used to distinguish suppressive cells from effector 
cells across species. Further Weiner and colleagues described a TGF-β secreting suppressive Th3 
type cell that could be induced in the periphery upon oral antigen feeding, but these cells 
expressed no specific markers that distinguished them from other T cells [113]. Additionally, 
Roncarlo and colleagues identified a separate type of suppressor T cell that could be induced 
after antigenic stimulation in the presence of IL-10 [86], which was later labeled as Tr1 cells. 
Acceptance of the existence of suppressive T cells (also termed as regulatory T cells) and 
extensive studies on them began following the identification of the CD25 surface protein as a 
discerning marker for regulatory T cells in 1995 by Sakaguchi and colleagues [114] (CD25 is 
expressed on activated effector T cells as well, but in a naïve uninfected state, CD25 expressing 
cells are predominantly suppressive). Since this landmark paper, thousands of scientific 
manuscripts have been published on regulatory T cells and these cells are now considered one of 
the central components of the mammalian immune system. Following the identification of CD4 
and CD25 expressing cells as regulatory T cells, multiple other types of regulatory cells have 
been described [115-117]. This dissertation will only focus on the FoxP3 expressing CD4+ 
CD25+ T cells, which are termed as “Treg” (acronym for regulatory T cells) henceforth. 
1.10.2 Regulatory T cell phenotype:  
Following the identification of CD25, researchers have been able to demonstrate that Treg 
express many other surface receptors at levels that are higher than naïve or effector T cells [118-
122]. Some of the most important of these receptors are: CTLA-4 (cytotoxic T lymphocyte 
 25 
antigen-4) – a surface receptor that binds to the co-stimulatory (signal 2) receptors on APC 
allowing it to influence DC and T cell behavior; GITR (glucocorticoid-induced tumor necrosis 
factor receptor-related protein) – suggested to play an important role in Treg suppressive 
function although the specific details are unclear; and FR4 (folate receptor 4) – a surface protein 
that is required for folic acid sensing and uptake, which in turn prolongs Treg survival. In 
addition to these proteins, Treg also express adhesion proteins (e.g. CD62L, CD103) and 
chemokine receptors (e.g. CCR7, CCR4, CCR5 e.t.c.) at high levels depending on state of 
activation and the need to migrate to specific tissues. It is noteworthy to mention that none of 
these receptors are unique to Treg, and are expressed by naïve or effector T cells, but generally at 
lower levels. To date, no surface protein has been identified that distinguishes Treg from other T 
cells. 
In 2003, three independent groups identified that Treg exclusively express the 
intracellular transcription factor FoxP3 (also known as scurfin) [123-125]. These studies 
provided evidence that FoxP3 expression determined both Treg phenotype and function. More 
specifically, deletion of the FoxP3 gene led to a failure in Treg development and a corresponding 
absence of suppressive function. Additionally, induction of FoxP3 in naïve T cells resulted in 
corresponding induction of suppressive function in those cells. Further, depletion of Treg from 
normal mice through blocking antibodies caused autoimmune disease.  Finally, transfer of these 
cells from wild type mice could mitigate autoimmune disease and restore immune homeostasis 
(reviewed in [126]). 
FoxP3-expressing Treg can further be divided into two specific subtypes: (i) natural Treg 
(nTreg) that arise in the thymus are also thought to express TCR specific for self antigen; (ii) 
peripherally induced Treg (or adaptive Treg, iTreg) that arise in the periphery. nTreg have been 
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described to be anergic under standard in vitro conditions [122], but are capable of robust in vivo 
proliferation. They require high levels of IL-2, TGF-β and possibly folic acid, among other 
factors, for their survival and proliferation [126]. iTreg are generated in vitro and in vivo upon T 
cell activation in the presence of TGF-β. iTreg can develop upon antigenic stimulation in an 
immunosuppressive environment rich in TGF-β in vitro [84-85], and in the presence of TGF-β 
and retinoic acid in vivo [88]. Another possible mechanism for their in vivo generation is their 
induction in the presence of nTreg, a phenomenon that is described as infectious tolerance [127]. 
FoxP3 expressing iTreg appear to function in a similar fashion to nTreg, but with an antigen 
recognition repertoire that is more diverse (against microbial antigens, allo-antigens, tumor 
antigens and possibly even self-antigen) [115].  Additionally, the long-term in vitro and in vivo 
stability (FoxP3 expression as well as suppressive capabilities) of iTreg remains questionable 
[128]. 
1.10.3 Treg function:  
The main function of Treg is to restore immune homeostasis by suppressing effector immune 
cells. Treg carry out their suppressive function using many different mechanisms (reviewed in 
[127, 129]), which can be broadly categorized as contact-dependent and contact-independent 
methods. 
1.10.3.1 Contact-dependent suppression  
(i) Treg suppression mediated through interactions with DC – Treg express CTLA-4 at high 
levels, and interactions with DC through CTLA-4 can lead to up-regulation of the immuno-
modulatory protein indoleamine 2, 3-dioxygenase or down-regulation of surface co-stimulatory 
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molecule expression on DC. Both of these conditions lead to an inability to activate T cells 
effectively and have the potential to induce T cell apoptosis [126, 130]. Alternately, Treg can 
interact with DC to prevent their proliferation or even directly lead to their apoptosis, as 
suggested by studies on complete removal of Treg from adult mice that show a marked increase 
in the numbers of DC in these animals[131]. Additionally, Treg might be able to simply 
outcompete T cells in their ability to interact with DC and prevent naïve T cell – DC interaction 
(suggested in [126]).  
 
(ii) Treg suppression mediated through interactions with T cells – Many activated Treg have 
been shown to express Granzyme B and Perforins on their surface, which can promote T cell 
apoptosis following Treg-T cell interaction [132-133]. It has also been suggested that upon on 
direct interaction, Treg and T cells form gap junctions through which Treg can deliver 
immunosuppressive molecules to T cells [134] or physically prevent them from proliferating 
[126].  
1.10.3.2 Contact-independent suppression:  
(i) Active Treg suppression mediated through release of immunosuppressive cytokines – 
Depending on the nature of inflammation, the tissue environment and the activation state, Treg 
are known to release a number of different immunosuppressive mediators that can actively 
modulate immune cell function. One of the most important factors is TGF-β, which has been 
suggested to be not only a suppressive mediator but also essential for Treg survival. IL-10 and 
adenosine are other factors that Treg secrete or use to modulate T cell responses [86, 134]. The 
secretion of these modulators causes a decrease in immune cell proliferation and generally 
suppresses inflammatory cytokine production [86, 135-136], both of which are essential for re-
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establishing homeostasis. Additionally, the secretion of immunosuppressive factors results in one 
of the most widely described modes of Treg suppression – “bystander suppression” [127]. In this 
type of suppression, Treg not only suppress antigen-specific responses, but also suppress antigen 
non-specific responses due to the establishment of an immunosuppressive environment. This 
mechanism allows Treg to directly control the suppression of many other immune cells such as 
CD8+ T cells, B cells, macrophages, and NK cells [137]. Further, using these mediators 
(especially TGF-β), Treg can induce naïve as well as effector T cells to become suppressive Treg 
cells, a phenomenon called “infectious tolerance” [126-127]. 
1.10.4 Regulatory T cell therapies in the clinic 
Given their unique capability in regulating the immune system, regulatory T cells are considered 
as one of the best candidates for tolerance inducing therapies for graft rejection as well as 
autoimmunity [126, 138-139]. Indeed, a significant amount of research has gone into developing 
Treg based cellular therapies for use in humans (reviewed in [138-139]). Recently, clinical trials 
on using Treg to treat graft versus host disease (GVHD) have begun in Germany (Edinger and 
colleagues) and the US (Blazar and colleagues) [138], and it is expected that such clinical testing 
will expand to other types of transplants as well as autoimmune diseases [138]. However, for the 
widespread clinical translation of Treg therapies, three major hurdles need to be cleared: (i) 
isolating Treg specifically in GMP conditions – as mentioned in previous sections, a surface 
marker for Treg has not been identified, which makes it difficult to isolate pure populations of 
Treg [138-140];  (ii) increasing Treg numbers ex vivo – given the small number of cells that can 
be isolated from the peripheral blood in humans, it is necessary to proliferate Treg ex vivo prior 
to adoptive transfer. Unfortunately, Treg do not proliferate efficiently under in vitro activating 
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conditions [122, 126, 140]; (iii) ensuring that Treg don’t lose their functional suppressive 
capacity in vivo following adoptive transfer – the single greatest fear associated with Treg 
cellular therapies is the loss of their suppressive capability and reversion to a effector T cell 
phenotype after adoptive transfer [138, 140]. 
Although there have been noteworthy developments in overcoming these challenges in 
the recent past (e.g. improved methods for GMP isolation of Treg [141-142] and ex vivo Treg 
expansion [143-145]), significant problems associated with Treg stability and the expense of 
Treg cell therapy still remain. Hence, alternatives to Treg cellular therapy are actively being 
sought. An interesting option would be to develop strategies that increase local numbers of Treg 
in vivo at the site of a transplant. Currently, there are no known strategies to manipulate Treg 
cells in vivo. The following chapters focus on the development of the first synthetic strategies to 
increase in situ numbers of Treg. 
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2.0  DELIVERY OF RAPAMYCIN TO DENDRITIC CELLS USING DEGRADABLE 
MICROPARTICLES 
2.1 INTRODUCTION: 
As highlighted in Chapter 1, graft rejection can be delayed and possibly prevented through the 
generation of tolerogenic DC that specifically suppress immune responses against the transplant. 
One potential method of generating tolerogenic DC is by using immunosuppressive drugs, such 
as rapa, to modulate DC function [30-31]. However, the problem of DC-specific delivery of rapa 
needs to be addressed, as systemic delivery of this drug is associated with adverse side effects 
[146-147].  
DC-specific delivery of therapeutic agent like rapa can be achieved through passive 
targeting, in which, the therapeutic is encapsulated into polymeric or lipid based vesicles (such as 
microparticles) that can specifically be taken up by phagocytic cells and are too large for non-
phagocytic cells to envelop (0.5-5 µm) [148]. The size of the microparticle is an important aspect 
to consider while developing DC-specific delivery vehicles, as: 1) if the particles are too small 
(nanoparticles) they will be taken up by many different cells of the body, 2) if they are too big 
(>10 μm) they will not be taken up by DC. We and others have previously shown that 
microparticles within the size range of ~1-10 μm are specifically taken up by phagocytic APC, 
such as DC [148-150]. Furthermore, it has been suggested that such microparticle-based delivery 
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vehicles can achieve markedly higher potency with orders of magnitude less drug as compared to 
systemic delivery or even local delivery, due to the capability for targeted and intracellular 
delivery of payload to phagocytes [151].  
Given this information, we hypothesized that intracellular delivery of rapa to DC using 
microparticles loaded with the drug would be better at inducing a tolerogenic phenotype when 
compared to treatment of DC with soluble rapa in vitro. In this chapter, we describe the 
development and characterization of an appropriately sized (1-10 µm diameter) microparticulate 
system for DC-specific intracellular delivery of rapa, to test the aforementioned hypothesis. 
2.2 METHODS: 
2.2.1 Microparticle Preparation 
Microparticles were prepared using the single emulsion/evaporation technique as described [152-
153]. Briefly, 200 mg poly(lactic-co-glycolic)acid (RG504H – viscosity 0.45-0.6 dl/g, 
Boehringer Ingelheim Chemicals Inc., Petersburg, VA) was dissolved in 4 ml dichloromethane 
(oil phase). One hundred μl of a stock solution of rapamycin (LC laboratories, Woburn, MA) in 
Dimethyl Sulfoxide (10mg/ml) was dissolved in the oil phase, which was then homogenized at 
10100 rpm for 1 minute in a 2% PVA (MW ~ 25,000, 98% hydrolyzed; Polysciences) solution, 
using a homogenizer (Silverson L4RT-A). This emulsion was immediately poured into 90 ml of 
1% PVA solution, and dichloromethane was allowed to evaporate. After 3 hours, the particles 
were centrifuged (1500g, 10 min, 4°C) and washed x4 in deionized water. Microparticles were 
then re-suspended in 5 ml of deionized water, frozen on dry ice and lyophilized (Virtis Benchtop 
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K freeze dryer, Gardiner, NY; operating at 60 mTorr). Fluorescently labeled rapamycin-
microparticles were prepared by adding 100 μl of 2mg/ml (in DMSO) Alexa Fluor 647 
carboxylic acid, succinimidyl ester (Invitrogen) to the oil phase along with rapamycin, and 
following the same protocol as above. 
2.2.2 Microparticle Characteristics 
Microparticles were sized and counted using volume impedance measurements on a Beckman 
Coulter Counter (Multisizer 3). Average size was determined by counting at least 10,000 
particles. Microparticle surface morphology and shape were examined using a scanning electron 
microscope (JEOL JSM-6330F, Peabody, MA). The surface charge of microparticles was 
determined by zeta potential measurements (ZetaPALS, Brookhaven Instruments).  
2.2.3 Measuring encapsulation efficiency  
Five mg of rapamycin-microparticles (rapaMP) were dissolved in 1 ml of acetonitrile (HPLC 
grade), sonicated for 5 min and left under constant vortex for 30 min. The amount of rapamycin 
was then determined by measuring absorbance of this solution at 278 nm using a UV-equipped 
plate reader (SpectraMax M5, Molecular Devices). Encapsulation efficiency was calculated as 
the ratio of rapamycin present inside particles to the amount of rapamycin that was initially 
added during microparticle preparation; and normalized based on the yield. 
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2.2.4 In vitro release studies  
The in vitro release profile of rapamycin from rapaMPs was measured as described. A known 
amount of rapaMP was suspended in a solution of 1ml of phosphate buffered saline (DPBS, pH 
7.4, GIBCO, Invitrogen), or 1 ml of 100mM phosphate buffer (pH 5) containing 0.2% Tween-80. 
These suspensions were placed on an end-to-end rotator, at 37 °C. At regular intervals, the 
particles were centrifuged, the supernatant collected, and the particles re-suspended in equal 
volume of the buffer. Rapamycin content in the supernatant was analyzed by measuring 
absorbance at 278 nm as described above. Tween-80 was added to maintain sink conditions, and 
prevent adhesion of rapamycin to the sides of the tubes used for measuring release. 
2.2.5 Dendritic cell (DC) cultures and exposure to MP 
Bone marrow-derived myeloid DC were propagated from C57BL/10 (B10) mice (The Jackson 
Laboratory, Bar Harbor, ME) and purified as described [154]. Briefly, single cell suspensions of 
B10 bone marrow were cultured for 7 days with 1000 Units/ml of GM-CSF and IL-4 in complete 
media supplemented with 10% FCS. On day 8 non-adherent cells were collected and CD11c+ 
cells positively selected using anti-CD11c-cojugated Miltenyi beads (Myltenyi Biotech Auburn, 
CA). Where indicated, blankMPs or rapaMPs were added (0.11 mg of rapaMPs to achieve a 5:1 
ratio of particles to DC) to the culture the day before harvesting, and the culture left undisturbed 
till subsequent experimentation. DCs exposed to 10 ng/ml soluble rapamycin (Sigma-Aldrich) 
were used as additional comparison group.  
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2.2.6 Live cell imaging 
One day after the addition of rapaMPs, DC were purified as previously indicated, and cultured 
for 2 hours over glass bottom culture dishes (MatTek Corporation, Ashland, MA). Adherent DC 
were then imaged using differential interference contrast microscopy (inverted Olympus 1X81). 
2.2.7 Flow cytometric analysis:  
Following incubation with blankMP or rapaMPs for either 1 day or 4 days, DC were collected 
from the cultures and viability determined by Annexin-V/7-aminoactinomycin D (7-AAD) 
staining. Collected cells were stained with FITC-conjugated anti-CD11c mAb (BD PharMingen), 
PE-conjugated AnnexinV and 7-AAD (Apoptosis Detection Kit, BD PharMingen), following the 
manufacturer’s instructions and then analyzed with a LSR-II flow cytometer (BD Bioscience).  
To determine the level of expression of cell surface stimulatory molecules, DC incubated 
with fluorescent-rapaMPs for 1 day were collected and stained with FITC-conjugated anti-
CD11c mAb, PE-conjugated anti-MHC-II, anti-CD86, or anti-CD40 (all from BD PharMingen), 
following manufacturer’s instructions and analyzed as above. For both the experiments FITC-
conjugated anti-CD11c mAb was used to gate for DC using flow cytometry. 
2.2.8 T cell isolation 
CD4+ T cells were purified from spleen and lymph node cell suspensions by negative selection. 
Non-CD4+ cells were labeled with anti-CD11b, anti-TER-119, anti-Gr-1, anti-I-A/I-E, anti-
CD8 , anti-B220, and anti-Gr-1 mAbs (all from BD Pharmingen). Following incubation with 
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anti-rat-IgG-Dynabeads (Dynal Biotech, Invitrogen), bead-bound cells were removed by 
magnetic isolation. Purity of CD4+ T cell preparation was assessed by flow cytometry and 
corresponded to 90%, reproducibly. 
2.2.9 Mixed leukocyte reaction (MLR) 
B10 DC (15,000), cultured for 1 day with rapaMPs (using different ratios of rapaMPs to DC), 
were mixed with 150,000 CD4 T cells (isolated from lymph nodes and spleen of normal BALB/c 
mice) in u-bottomed 96 well culture plates. The cells were co-cultured in complete RPMI 1640 
(GIBCO, Carlsbad, CA), supplemented with 10% fetal calf serum, for 3 days following which 
tritiated thymidine was added. After 16 hrs, the amount of thymidine incorporated into the cells 
was measured using a Wallac 1205 Betaplate analyzer. A no treatment (NT) group consisting of 
DC that were not exposed to any particles, and DC cultured with blank particles (5:1 – particle to 
DC ratio) served as a negative controls. A DC group treated for 1 day with soluble rapamycin 
(10ng/ml) acted as a comparative control.  
2.2.10 Statistics 
Statistical analysis was performed using the 2-tailed Student’s t-test, and all results are expressed 
as ± 1 SD. Standard deviation was calculated based on n=3 experiments, unless otherwise stated. 
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2.3 RESULTS 
2.3.1 Microparticle characteristics 
Rapamycin-encapsulated PLGA microparticles (rapaMP) were prepared successfully using a 
single emulsion/evaporation technique. These particles were sized to be 3.4 ± 1.65 μm (diameter) 
using volume impedance measurements on a Beckman Coulter Counter. SEM images of these 
particles (Figure 3) show smooth surface morphology and confirm the size obtained from 
volume impedance measurements. The size distribution observed in the SEM images is 
characteristic of the microparticle synthesis procedure described above, and has been reported 
elsewhere [152, 155-156]. Further, the zeta potential of these rapaMPs was determined to be -
35.38 ± 4.49 mV (n=4 particle sets). 
 
 
Figure 3. Scanning electron micrographs of rapamycin 
containing PLGA microparticles. 
Representative images confirm that the particles exhibit surface 
integrity.  Also, sizes are consistent with measurements via 
volume impedance (Avg. Vol. Dia – 3.4 μm). 
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2.3.2 Encapsulation efficiency  
Encapsulation efficiency of rapaMP was determined to be 73.95 ± 5.43%. The presence of 
rapamycin inside microparticles was further confirmed by tandem mass spectroscopy analysis 
(data not shown). Based on the volume impedance measurements and encapsulation efficiencies, 
the amount of rapamycin in each rapaMP was calculated to be approximately 50 femtograms. 
2.3.3 In vitro release profile  
The release rate of rapamycin from rapaMPs was studied in both pH 7.4 and pH 5 buffer. It has 
been reported previously that DC efficiently phagocytose PLGA microparticles (3-4 µm in size) 
in 4-5 hrs, and that the particles may remain inside phagosomes (pH ~ 5) [149, 157]. Hence, to 
replicate intra-phagosomal pH conditions in vitro, release was studied in a pH 5 buffer. There 
were no significant differences observed in the release rates between pH 7.4 and pH 5 buffers 
(Figure 4). The release appeared to follow Fickian diffusion kinetics, and the calculated values of 
diffusivity of the drug in the polymer matrix were found to be in the same order of magnitude, as 
predicted by theoretical correlations developed by us and others [158-160].  The pH of the 
supernatant was measured to be stable throughout the release study (data not shown). 
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Figure 4: In vitro controlled release of rapamycin from small-rapaMPs in pH 5 and pH 7.4 buffer. 
Percentages are based on amount encapsulated. 100% indicates ~3.7 µg of rapamycin/mg of rapaMPs – 
the maximum amount that would be released if the particles degraded completely. Standard deviations are 
based on n = 6 samples for release at pH 7.4, and n=3 samples for release at pH 5. 
2.3.4 Live cell imaging and apoptosis level 
Reports in the literature have previous demonstrated that PLGA microparticles are phagocytosed 
by DC and can be identified inside these cells [149, 161]. Figure 5 shows images of live DC that 
were exposed overnight to different amounts of rapaMPs. These images show that, for any given 
ratio (number of particles: number of DC, adopted during the co-culture phase), a certain degree 
of variability in the number of particles phagocytosed by individual DC was evident. However, a 
general direct correlation appeared between the co-culture ratio and the average number of 
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particles internalized. Additionally, we observed that when a particle:DC ratio of 5:1 or 10:1 was 
used, the majority of DCs internalized at least one particle. 
NT
1:1 2:1
5:1 10:1
   
 
 
Figure 5: Representative images of live DC cultured for 1 day with rapaMPs. 
NT (no treatment) implies that no particles were added to these DC cultures. The ratios 
indicate the number of particles added to the number of DC. Scale = 50 μm 
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Next, it was determined if the phagocytosis of blankMPs or rapaMPs leads to DC death. 
Initial trypan blue exclusion studies on cultures treated with different particle:DC ratios showed 
a small percentage of DC positive for trypan blue. This number was not significantly different 
from the control population of non-treated DC at any ratio tested (data not shown). To further 
investigate the status of DC exposed to MPs, we collected cells after 24 hours or 96 hours of co-
incubation (particles and DC) and stained them with FITC-conjugated anti-CD11c mAb, 
Annexin-V (AnnV) and 7-aminoactinomycin D (7-AAD). FITC-conjugated anti-CD11c mAb 
was used to gate DC using flow cytometry, as CD11c is a DC-restricted marker. The 
combination of the other two dyes allowed the discrimination of viable DC (AnnV- 7-AAD-) 
from those that were either entering apoptosis (AnnV+ 7-AAD-), in late apoptosis (AnnV+ 7-
AAD+), or necrotic (AnnV- 7-AAD+). As observed from the AnnV/7-AAD profile of CD11c+ 
cells, 1 day after co-incubation (Figure 6A and Table 1) the proportion of apoptotic cells (early 
and late) among rapaMP-loaded DC was not different from that of untreated and blankMP-
loaded DC. After 4 days of co-incubation (Figure 6B and Table 1), the apoptotic level of 
untreated or blankMP-loaded DC was not significantly different. This indicated that the process 
of MP phagocytosis per se was not harmful to the cells. In the rapaMP group, however, a 
significant increase in the proportion of early apoptotic cells was evident in comparison to 
untreated and blankMP groups. As blankMP phagocytosis did not induce such alteration, the 
pro-apoptotic effect observed is attributable to intracellular release of rapamycin. 
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Figure 6: Annexin-V and 7-AAD staining of DC to examine potential toxicity of rapaMPs. 
Apoptosis of DC incubated for (A) - 1 day, or (B) – 4 days with different number of rapaMPs was 
compared to untreated DC. Flow diagrams were generated by gating on CD11c+ (DC restricted 
marker) cells. 
A
B
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Table 1: Quantitative analysis of apoptosis levels in DC that have phagocytosed rapaMPs. 
Live cells represent % cells that are AnnV- 7-AAD-, early apoptotic represents % cells that are AnnV+ 7-
AAD-, late apoptotic represents % cells that are AnnV+ 7-AAD+, and necrotic represents % cells that are 
AnnV- 7-AAD+. Both rapaMP and blank MP were added at a ratio of 5:1 (particle to DC). SD are based 
on n=3 experiments. * indicates comparison between rapaMP (4 day) and NT (4 day) groups - p<0.05, 
and ** indicates comparison between rapaMP (4 day) and blank MP (4 day) groups – p<0.05. 
 
 
2.3.5 RapaMP phagocytosis alters DC functionality  
The functional modulation of DC by rapaMPs was characterized in vitro using a mixed leukocyte 
reaction in which DC from one mouse strain (B10) were treated overnight with different ratios of 
rapaMP:DC and then co-cultured with CD4+ T cells isolated from secondary lymphoid organs of 
a different mouse strain (BALB/c). T cell proliferation (an indicator of DC stimulatory capacity) 
was assessed by cellular incorporation of radioactive thymidine after 3 days of co-culture (a total 
of 4 days after addition of rapaMPs to the DCs). As shown in figure 7, a reduction in T cell 
proliferation that correlated with the rapaMPs:DC ratio used, was observed. Over 5 times 
reduction in the ability of rapaMP-loaded DC (ratio of 5:1 and 10:1) to induce T cell 
Live cells Early apoptotic Late apoptotic Necrotic
NT (1 day) 91.1 ± 1.6 5.2 ± 0.3 3.2 ± 1.0 0.5 ± 0.5
Blank MP (1 day) 89.2 ± 6.0 6.2 ± 2.4 3.7 ± 2.8 0.8 ± 0.8
rapaMP (1 day) 87.2 ± 7.2 7.4 ± 3.4 4.0 ± 3.1 1.3 ± 1.4
NT (4 day) 84.8 ± 0.5 8.2 ± 0.7 5.2 ± 0.1 1.9 ± 1.2
Blank MP (4 day) 83.7 ± 1.1 8.5 ± 0.6 6.0 ± 1.4 1.8 ± 0.4
rapaMP (4 day) 74.3 ± 7.0 12.2 ± 1.0*, ** 10.3 ± 3.1 3.3 ± 2.9
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proliferation (p<0.005) was observed when compared to blank particle-loaded or non-treated 
DC. Further, figure 7 shows that rapaMP treatment (at 5:1 and 10:1 ratio) resulted in 
significantly greater inhibition of T cell stimulatory function (about 2.5 times greater reduction in 
T cell proliferation) than that achieved with soluble rapamycin-treated DC (p<0.01). Based on 
the encapsulation efficiency and assuming that the rate of drug release is accurately represented 
by the profile described in figure 4, we calculate that the amount of rapamycin delivered to DCs 
by rapaMP is approximately 3 ng/ml/day, while the amount added in the soluble rapamycin-
treated DC group was 10 ng/ml. 
 
 
Figure 7: A mixed leukocyte reaction indicating the amount of radioactive thymidine incorporated 
into responding T lymphocytes. 
DC were loaded with rapaMPs using the indicated MP:cell ratio and then used to stimulate allo-reactive 
CD4+ T cells. NT (no treatment) group was assigned the value of 100% and all other percentages are 
normalized based on this value. The ratio of MPs to DC in the blank particles group is 5:1. Standard 
deviations are based on n = 6 experiments per group. * indicates comparison between 5:1 and NT groups - 
p <0.005; ** indicates comparison between 5:1 and soluble Rapa treatment groups - p < 0.01. 
*
**
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2.3.6 RapaMP’s lower expression of cell-surface stimulatory molecules 
To investigate the mechanism behind functional modulation of DC loaded with rapaMPs, the 
expression of cell-surface co-stimulatory molecules (activation markers) was examined. Particles 
were loaded with Alexa Fluor 647 (A647) to track percentage of DC that have taken up particles 
and also determine the co-localization of particle uptake with any differences in cellular 
phenotype.  Flow cytometric analysis revealed that DC that had taken up fluorescently stained 
rapaMPs (A647 high) had lowered expression of CD86, MHC-II and CD40 (common 
stimulatory molecules expressed on DC) when compared to DC that were A647 low (Figure 8). 
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Figure 8: Flow Cytometric Analysis of DC activation markers on cells that have taken up fluorescently 
labeled rapaMPs (A647+). 
Flow diagrams were generated by gating on CD11c+ and Alexa-fluor 647high or Alexa-fluor 647low, as described in 
the top-center plot. Numbers on flow diagrams indicate mean fluorescence intensity values. DC were cultured with 
rapaMPs at a ratio of 5:1 (rapaMPs to DC) for 24 hours, prior to flow analysis. 
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2.4 DISCUSSION 
Microparticles composed of the degradable polymer PLGA have been widely used for controlled 
release of drugs and proteins [44-45]. Appropriately-sized microparticles have also been used 
specifically for targeted delivery of drugs, antigens and DNA to phagocytic cells [148-149, 157, 
161-162]. The size of the polymeric particles has an important bearing on their ability for long-
term release, total payload delivered and specific targeting to phagocytic cells. If the size is too 
small, as is the case with nanoparticles (~200 nm or lower), it is widely believed that they are not 
suited to act as long term delivery vehicles [148, 163-164].  Furthermore, nanoparticles are 
typically taken up by all cells capable of endocytosis [148], and although such systems may 
deliver drugs to dendritic cells if placed in a physiologic milieu with large numbers of resident 
dendritic cells (e.g. the dermis) [57-58, 165] they have no inherent targeting capabilities per se. 
Conversely, if particles are too large (>10 μm), they cannot be internalized by phagocytic cells 
[166-167]. Hence, for applications where long term and phagocytic cell-specific targeted 
delivery is desirable (such as transplantation and autoimmune disease immunotherapy, or anti-
tumor immunity) it is imperative that drugs are encapsulated into micron-sized particles (~ 1-10 
μm).  
One of the recently developed approaches in transplantation and autoimmune disease 
immunotherapy involves use of dendritic cell (DC)-based therapeutics [65, 168]. Previous 
reports in the literature have shown that DC cultured with specific agents, such as the 
immunosuppressive drug rapamycin, have altered function and can be used to suppress 
transplant rejection and promote donor-specific tolerance [30, 32, 104]. Our long term goal was 
to create a system capable of specifically targeting DC in vivo and then sustaining intracellular 
delivery of rapamycin to produce a more pronounced effect with respect to suppression of 
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transplant rejection and promotion of tolerance without systemic immunosuppression. In this 
study, the hypothesis that intracellular delivery of rapamycin to DC using appropriately sized 
microparticulates is effective at inhibiting an important initial step in the onset of transplant 
rejection - T cell activation, was tested. 
The aforementioned experiments demonstrate that rapamycin can be encapsulated and 
controllably released from appropriately sized PLGA microparticles. PLGA was the polymer of 
choice as it does not activate DC [149], and allows for intracellular release of drug over extended 
periods as shown in figure 4. A Fickian release that lasts for about 3 weeks was observed, which 
is similar to a previously reported release profile for cyclosporine (a drug with similar mol. Wt. 
and hydrophobicity as rapamycin) [152]. Further, the release can be modulated as desired by 
changing the molecular weight of PLGA used to make the microparticles.  Additionally, the data 
suggests that rapaMPs are associated with a more pronounced effect on DC when compared to 
conventional rapamycin treatments. Previously, our collaborators have shown that DC treated 
with soluble rapamycin are characterized by a lower capacity to activate T cells [30, 32]. 
However, in comparison to soluble rapamycin-treated DC, rapaMP-loaded DC exhibit 
significantly higher capacity in preventing T cell activation (Figure 8). Annexin V and 7AAD 
staining was used to analyze if this reduction was due to an increase in DC apopotosis in the 
presence of rapaMPs over the 96 hour period (Figure 6 and Table 3). Figure 4A shows that 
annexin V and 7AAD profiles for untreated and rapaMP-loaded DC following 1 day of co-
incubation are similar, confirming that phagocytosis of rapaMPs does not cause increase in DC 
apoptosis. After 4 days of co-incubation, a small increase in apoptosis of rapaMP-loaded DC is 
observed (Figure 6B and Table 1). Since the number of apoptotic cells in the untreated and blank 
particle-loaded DC groups is not different, the observed increase in apoptosis of rapaMP-loaded 
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DC is most probably due to the presence of rapamycin. Importantly, it has been previously 
shown that the presence of soluble rapamycin in DC cultures leads to increase in apoptosis rates 
similar to what is depicted in figure 6B for rapaMP [169]. In light of this data, it could be 
concluded that apoptosis alone is not responsible for the effects of rapaMP-loaded DCs when 
compared to soluble rapamycin. 
It should be noted that the observed increase in inhibitory capacity when using rapaMPs 
is pronounced (Figure 7) despite the fact that the theoretical quantity of rapamycin delivered is 
equal to or less than the soluble rapamycin group (amounts calculated based on encapsulation 
efficiency and cumulative release from rapaMPs). It is likely that this superior inhibitory effect is 
due to greater intracellular availability of the drug, as it is known that rapamycin inhibits DC 
function through its action on an intracellular protein kinase [30, 32]. 
One possible mechanism by which the function of DC is altered upon rapaMP 
phagocytosis is the limited expression of certain necessary stimulatory modalities on the cell 
surface (Figure 8). It is well known that activation of T cells by DC requires the expression of 
MHC (signal 1) in the presence of other co-stimulatory molecules (signal 2). Flow cytometric 
analysis reveals that the expression of both MHC-II and co-stimulatory molecules (CD86 and 
CD40) is substantially lower in DC that have taken up rapaMPs (Figure 8).  Although it cannot 
be ruled out that rapaMPs also affect DC in other ways, agents which specifically down-regulate 
co-stimulation have been identified as promising candidates for clinical transplantation 
immunotherapy [31, 65] and current phase I clinical trials are underway for autoimmune Type I 
diabetes that utilize antisense oligonucleotides that knock down CD40 and CD86 [102]. 
The results may also have implications for DC-specific delivery of many other immuno-
modulatory agents that act intracellularly, such as aspirin, corticosteroids, and vitamin D3 
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analogues [31]. Thus, it is possible that appropriately-sized degradable microparticulates could 
be used as a modular platform technology to deliver any number of the newly-identified agents 
that exhibit immuno-modulatory effects through interactions with DC.  
In conclusion, this study demonstrates the successful preparation and characterization of 
rapaMPs that can be phagocytosed by DC. The results show that the release of rapamycin in pH 
7.4 and pH 5 buffers lasts for about 2-3 weeks. Additionally, it was observed that rapaMP-loaded 
DC have a much lower capacity to induce proliferation in T cells than DC exposed to soluble 
rapamycin, in vitro. This effect may be mediated by down-regulation of surface co-stimulatory 
molecules.  These microparticles have the potential to either be preloaded into DC ex vivo or to 
passively target DC in vivo as an antigen presenting cell-specific immunotherapy for 
transplantation and autoimmune diseases. 
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3.0  BIO-INSPIRED CONTROLLED RELEASE FORMULATIONS FOR THE 
RECRUITMENT OF REGULATORY T CELLS (TREG) 
3.1 INTRODUCTION 
The importance of Treg in determining immune homeostasis in the healthy steady state was 
discussed in detail in Chapter 1 (Section 1.10). This chapter describes the development and 
testing of a technology that would increase Treg numbers at a local site in vivo in an attempt to 
induce a homeostatic environment.  
The absence or increased presence of Treg in specific tissues has been shown to lead to 
diverse outcomes [126, 170-171]. For example, Treg deficiency is a causative factor for 
autoimmune disease [171-172].  Conversely, enriched numbers of Treg at tumor sites results in 
detrimental suppression of tumor-specific immunity [173]. Although it is not clear how Treg 
reduction in self tissues occurs, there is some indication as to how these cells are enriched in 
tumors. Specifically, a wide variety of tumors release the chemokine CCL22 [173-174], which is 
responsible for tumor-specific migration of Treg and corresponding tumor-specific immune 
evasion.  
From the perspective of therapeutic intervention for organ allograft rejection and 
autoimmune diseases, the following question arises; would it be possible to attract Treg to the 
site of interest in a fashion similar to that used by tumors, to suppress local immunity? One 
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potential method of achieving site-specific localization of Treg is the establishment of a CCL22 
gradient through controlled release technology. Herein, we demonstrate that a CCL22-based 
sustained release vehicle can indeed be used for local recruitment of Treg and suppression of 
immune reactivity. 
3.2 MATERIALS AND METHODS 
3.2.1 Animals 
Female BALB/c and C57Bl/6 mice (6-8 weeks old) were purchased from Charles River 
Laboratories (Wilmington, MA); FVB mice were obtained from Taconic (Hudson, NY) and 
FVB.luc+ mice were from Xenogen (Caliper LifeSciences, Hopkinton, MA)[175]. All animals 
were maintained under specific pathogen free conditions at the University of Pittsburgh. 
Experiments were conducted in accordance with the National Institutes of Health Guide for Care 
and Use for Laboratory Animals and under Institutional Animal Care and Use Committee-
approved protocols. 
3.2.2 Microparticle Preparation 
Microparticles (MP) containing rmCCL22 (R&D systems, Minneapolis, MN) were prepared as 
described [176]. Briefly, 200 µl of a 15mM NaCl solution containing 5 µg of CCL22 and 2 mg 
of BSA was mixed with 200 mg of Poly (lactic-co-glycolic) acid (RG502H, Boehringer 
Ingelheim, Petersburgh, VA) dissolved in 4 ml of dichloromethane.  This mixture was sonicated 
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for 10 sec (to form the first emulsion of water-in-oil) before being poured into 60 ml of 2% PVA 
solution (M.W. ~25,000, 98 mol. % Hydrolyzed, PolySciences, Warrington, PA) being 
homogenized (Silverson L4RT-A) at 3000 rpm. Following homogenization for 1min (to form the 
second emulsion), the solution was mixed with 1% PVA and the dichloromethane was allowed 
to evaporate. After 3 hr, the freshly formed MP were centrifuged and washed (x4) in de-ionized 
(DI) water. The MP were then re-suspended in 5 ml of DI water, frozen on dry ice and 
lyophilized (Virtis Benchtop K freeze dryer, Gardiner, NY; operating at 100mTorr). 
Fluorescently-labeled CCL22MP (CCL22MP-680) were prepared by adding 50µg of dextran-
alexa fluor® 680 (M.W. 10,000, Invitrogen, Carlsbad, CA) to the 200µl aqueous solution 
containing CCL22. 
3.2.3 Microparticle Characterization 
The surface morphology of CCL22MP was characterized using a scanning electron microscope 
(JEOL JSM-6330F, Peabody, MA) and CCL22MP size distribution measured using volume 
impedance measurements on a Beckman Coulter Counter (Multisizer-3, Beckman Coulter, 
Fullerton, CA). The amount of CCL22 encapsulated was determined by degrading 5mg of 
CCL22MP in 10ml of 0.05N NaOH + 0.5% SDS solution for 2 hr, followed by quantifying the 
amount of chemokine in the supernatant using a CCL22-specific ELISA kit (R&D systems, 
Minneapolis, MN). In vitro release characteristics were measured by suspending ~7mg of 
CCL22MP in 1ml phosphate buffered saline (PBS) on an end-to-end rotator at 37°C. At different 
time intervals, the suspensions were centrifuged, the supernatant collected, and the CCL22MP 
re-suspended in 1ml PBS. The amount of CCL22 in the supernatant was determined by ELISA. 
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3.2.4 Alloactivated regulatory T cell (AATreg) cultures: 
CD4+ CD25+ regulatory T cells (Treg) were isolated from the spleens and lymph nodes of 
FVB.luc+ mice using the following procedure. CD4+ T cells were enriched using the Dynal® 
mouse CD4+ negative selection kit (Invitrogen, Carlsbad, CA) as per the manufacturer’s 
instructions. CD25+ T cells were isolated from the CD4+ cell pool by labeling the cells with anti-
CD25-PE, followed by addition of anti-PE beads (Miltenyi) and separating the bead-labeled cells 
using a MACS ® column (Miltenyi, Auburn, CA). CD4+ CD25+ (enriched Treg) were then 
cultured for 10 days with immature allogeneic-DC (propagated from the bone marrow of 
BALB/c mice [177]) in complete media (containing 10% FBS) and 1000 U recombinant human 
IL-2. At the end of the culture period, anti-CD11c-labeled beads (Miltenyi) were added to the 
cells and DC removed using an autoMACSTM separator (Miltenyi). The isolated, alloactivated 
Treg [178] were then prepared for in vivo injections. 
3.2.5 In vivo Treg migration 
CCL22MP-680 (2.5µg suspended in 50µl of PBS) was injected into the triceps surae of FVB 
mice on day -3 or day -6 (Figure 2a or supplementary Figure 3a schematic). BlankMP-680 
injections in the contra lateral limb served as an internal control. AATreg were injected i.v. on 
day 0 (2x106 cells in 200 µl of PBS), followed by mature allogeneic DC injection (1x106 cells in 
200 µl of PBS). Non-invasive, live animal bioluminescence imaging was performed at defined 
time intervals using Xenogen Vivovision (IVIS 200, Caliper LifeSciences, Hopkinton, MA). 
Luc+ Treg were detected by injecting 200 µl of luciferin (Caliper LifeSciences) 10 min prior to 
imaging. The position of each mouse remained unchanged, while both fluorescence and 
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luminescence imaging was performed. Images acquired from the live animal imaging apparatus 
were analyzed using Igor Pro Living Image® 2.60.1 (Caliper LifeSciences). Contours of 
equivalent fluorescence signal from each leg were automatically drawn by the software, and then 
applied to the luminescence images to determine co-localization of AATreg with particle depots. 
Statistical analysis was performed using the Student’s ‘t’ test on avg. luminescence 
measurements obtained from the BlankMP-680 and CCL2MP-680 groups. 
3.2.6 Allogeneic cell transplant studies 
Either CCL22MP-680 or BlankMP-680 was injected subcutaneously into FVB mice 4 days prior 
to the implantation of allogeneic cells. Transgenic luciferase expressing lewis lung carcinoma 
cells (1x106; originally derived from C57Bl\6 mice) were injected at the sites of particle injection 
(area of particle localization was determined using fluorescence imaging) in 100 µl of PBS. At 
defined time intervals bioluminescence imaging was performed as described previously. For 
analysis of acquired images, equivalent circles enveloping the area of luminescence signal were 
drawn and average luminescence (photons/sec/cm2/Sr) measured (avg. luminescence 
measurements negate any differences in signal that may arise due to variations in selection of the 
area of luminescence). Data are reported as normalized avg. luminescence, where the 
luminescence intensity measured from any given mouse on any given day was divided by the 
luminescence intensity measured for the same mouse on day 1. Statistical analysis was 
performed on the normalized data using the Mann-Whitney U test. 
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3.3 RESULTS AND DISCUSSION 
Sustained release of CCL22 was achieved by loading the chemokine into degradable poly (lactic-
co-glycolic) acid-based microparticles (CCL22MP). Scanning electron micrographs of intact MP 
indicate that they are spherical and slightly porous (Figure 9a).  
 
 
Figure 9: CCL22MP characteristics. 
A – scanning electron micrograph of an intact CCL22MP showing its external porous 
structure. Inset is zoomed-out detail of main image. B - representative volume-averaged size 
distribution of CCL22MP; average volume diameter measurements ± SEM are based on n=6 
particle sets. C – release kinetics of CCL22MP as measured in PBS; errors bars represent 
cumulative SEM based on n=3 experiments.  
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The surface of CCL22MP was specifically formulated to be porous, to allow continuous release 
(without periods of lag) of chemokine (Figure 9b), as guided by new mechanistic descriptions of 
how controlled release of proteins occurs in such systems [159-160]. Further, the particles were 
designed to be large enough to avoid uptake by phagocytic cells and to prohibit their movement 
across vascular endothelium, with consequent immobilization at the site of injection (Figure 9c).  
In order to test the ability of CCL22MP to attract Treg, an in vivo adoptive transfer model 
coupled with non-invasive live animal imaging was used. Fluorescently labeled CCL22MP were 
injected into the triceps surae of normal FVB mice followed by i.v. infusion of ex vivo-
alloactivated Treg [178] (AATreg) that constitutively express the luciferase gene. The migration 
pattern of these bioluminescent AATreg was studied following the injection of non-labeled 
mature allogeneic dendritic cells (DC), which provide an activation stimulus (Figure 10a). Soon 
after DC stimulation, a significantly greater number of AATreg was recruited to the site of 
CCL22MP injection (Figure 10b) compared to an internal control of microparticles lacking 
CCL22 (BlankMP). Further, upon analyzing the kinetics of migration, we determined that 
residence time of Treg at the site of recruitment was transient (Figure 10c). This type of 
recruitment pattern is not uncommon and has been observed for other inflammatory cell types 
[179]. Nevertheless, we did consider the possibility that this transient response may be a result of 
short-term release of CCL22 from the MP in vivo (<10 days). However, delaying adoptive 
transfer of AATreg post-CCL22MP injection revealed that these cells could also be recruited at 
later time points (Figure 11), and that the residency remained transient. It is also possible that the 
absence of antigen-specific stimulation at the site of CCL22MP injection led to the decline in 
AATreg. Presumably, the presence of Treg could be extended in a stimulatory micro-
environment, a hypothesis we are currently testing. 
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Figure 10: In vivo migration of Treg towards CCL22MP. 
A – schematic describing the design of the live animal imaging experiment; ‘Luc+ Treg’ indicates Treg isolated 
from transgenic FVB.luc+ mice that constitutively express the luciferase gene. B – representative fluorescence 
(red-gold) and luminescence images (blue-yellow) showing localization of particles and Treg, respectively; 
fluorescence images were used to outline (red-line) areas of particle localization (Igor Pro Living Image® 2.60.1) 
and these outlines were super-imposed on luminescence images taken with the mouse in identical position to 
demonstrate co-localization of Treg and CCL22MP. C – kinetics of Treg migration towards the injected MP; 
average radiance measurements obtained from the luminescence images are displayed as a ratio of CCL22MP to 
BlankMP based on n=6 mice ± SEM at all time points except, day 3 and day 5, where n=3 ± SEM. * indicates p = 
0.04 comparing average radiance measurements obtained from CCL22MP with BlankMP using a two-tailed, 
paired Students‘t’ test. 
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Figure 11: Delayed in vivo migration experiments. 
Schematic describing the design of the delayed migration experiment - AATreg were adoptively 
transferred i.v. 6 days after injection of CCL22MP. Representative fluorescence (left) and luminescence 
(right) images were obtained 6 days after AATreg infusion showing that the cells migrated toward and 
co-localize with CCL22MP at later time points (12-13 days post particle injection) as well. 
BlankMP CCL22MP BlankMP CCL22MP
Day 6
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Figure 12: CCL22MP delays rejection of allo-transplants. 
A – representative luminescence images of mice injected with particles and luciferase-expressing allogeneic 
lewis lung carcinoma (LLC) cells.  B – quantitative analysis of the kinetics of allo-transplant rejection; 
normalized luminescence was calculated by determining the ratio of luminescence on any given day to the 
luminescence on day 1 after LLC cell implantation. Error bars indicate SEM based on n = 11 mice (for 
BlankMP and CCL22MP groups) and n = 5 mice for the bolus CCL22 group. * indicates p < 0.05 based on 
Wilcoxon rank-sum test for null hypothesis that normalized luminescence for CCL22MP is the same as that 
of BlankMP or bolus CCL22, and # p < 0.03 for comparison between CCL22MP and BlankMP only. 
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Although tracking populations of endogenous Tregs is much more difficult than 
adoptively transferred luminescent Tregs, it is conceivable that their end effects on the local 
microenvironment can be readily detected.  Indeed, tumors increase the likelihood of their 
survival through release of CCL22 and corresponding recruitment of endogenous Tregs [173-
174].  For this reason, we wished to determine if we could reproduce this effect in an allogeneic 
cell transplant model.   
Specifically, allogeneic luciferase-expressing Lewis lung carcinoma cells (which do not 
produce CCL22 endogenously) were implanted subcutaneously into mice at the site of 
CCL22MP injections (or for comparison BlankMP or Bolus CCL22 as controls), and the time to 
rejection was recorded using non-invasive live imaging. In support of our hypothesis, we 
observed that the rejection rates were significantly slower in the CCL22MP group when 
compared to both bolus CCL22 and BlankMP controls (Figure 12a and 12b). 
Potential therapeutic implications of a degradable controlled release formulation capable 
of recruiting Treg in vivo are manifold. One obvious application is the use of CCL22MP in 
combination with an infusion of Treg expanded ex vivo. Current pre-clinical data suggest that 
freshly-isolated or ex vivo-expanded Treg infusion can prevent organ transplant rejection or 
suppress autoimmune diseases. However, challenges such as obtaining adequate numbers and 
highly-purified populations of Treg have hindered progress into clinical trials [138, 180].  Using 
formulations that release CCL22, it may be possible to lower the numbers of injected Treg, or 
potentially use populations with lower purity. Another use of CCL22MP would be to attract 
endogenous Treg populations, wherein these formulations have the potential to function as “off-
the-shelf” therapeutics for the treatment of a wide variety of disorders associated with 
unrestrained immune reactivity.   
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A potential drawback of using a CCL22 sustained release vehicle is that the receptor for 
this chemokine (CCR4) is expressed on both activated Treg and activated effector T cells [181], 
which suggests that both these cell populations would be attracted towards CCL22MP.  Yet in 
vivo studies suggest that CCL22 production associated with tumors [174, 182] or long-surviving 
allografts [183] result in recruitment of Treg leading to local immunosuppression.  One possible 
explanation for these results is that Treg express significantly more CCR4 than effector T cells 
[182] (Figure 13).   
 
 
Figure 13: CCR4 expression is higher on Treg. 
Surface expression of the chemokine receptor CCR4 was determined on 
FoxP3 expressing CD4+ T cells (Treg) and FoxP3 – CD4+ T cells (effector T 
cells). MFI indicates median fluorescence intensity. Normalized MFI was 
calculated by determining the ratio of  MFI on CCR4 stained cells to the 
MFI on the isotype stained cells. # indicates p<0.005; n =5 (based on 2 
independent experiments). 
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Further, it has been suggested that an optimal ratio of Treg to effector T cells, and not 
complete absence of effector T cells, is necessary for effective local suppression of immunity 
[172, 180].  Regardless, if local effector T cells abrogate a suppressive environment, CCL22MP 
can easily be modified to simultaneously release immunosuppressive agents (such as rapamycin 
as described in Chapter 2 and [29]) to inhibit these effector T cells in situ, thereby assisting Treg 
to control adverse immune responses. 
In conclusion, we demonstrate that site-specific attraction of Treg leading to local 
immunomodulation can be achieved in vivo using CCL22MP. These bio-inspired controlled 
release formulations are particularly attractive as modular platforms for therapeutic development, 
as well as tools to study Treg-dependent modulation of immune responses in situ. 
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4.0  CHARACTERIZING THE PHENOTYPE AND FUNCTIONAL CAPABILITIES 
OF RAPAMYCIN INDUCED REGULATORY T CELLS 
4.1 INTRODUCTION: 
Treg-based therapies are widely regarded as promising treatment options for autoimmunity and 
transplant rejection [138, 180, 184].  Currently, several therapies involving the use of ex vivo 
expanded Treg are being tested in clinical trials [138, 185]. However, there are significant 
barriers to ex vivo Treg-therapies such as difficulty in isolating pure populations of these rare 
cells and expanding them to sufficiently large numbers while maintaining their phenotype and 
function [138, 140].   
One possible alternative to circumvent these issues is to generate adaptive or induced 
Treg (iTreg) from the patient’s own naïve T cells either ex vivo or in vivo. Past reports have 
demonstrated that IL-2 and transforming growth factor β1 (TGF- β) can induce Treg phenotype 
and functional characteristics in naïve T cells upon in vitro stimulation [84, 186]. However, 
TGF-β induced Treg (TGFβ-iTreg) have been shown to be unstable in long term in vitro cultures 
and upon antigenic re-stimulation [128]. Additionally, the presence of inflammatory cytokines 
such as IL-6 can antagonize TGF-β mediated induction of Treg [187-188], making the presence 
of such inflammatory mediators a potential impediment to inducing Treg in vivo at the site of the 
disease. 
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Numerous reports in the literature suggest that these problems can be overcome through 
the use of small molecules that work in concert with TGF- β to induce Treg. For example, all-
trans retinoic acid (RA) is known to potently synergize with IL-2 and TGF-β to induce FoxP3 
expression in naïve T cells [189-191] and allow for induction of Treg even in the presence of 
inflammatory cytokines. Thorough characterization of the phenotype and function of RA induced 
Treg (RA-iTreg) demonstrates that they are better suppressors and more stable than TGFβ-iTreg 
[190, 192].  Nevertheless, their use is limited by the fact that RA-iTreg are known to primarily 
migrate to the mucosal tissues in the gut [189-190]. Further, recent evidence suggests that 
depending on the immunological microenvironment RA can induce inflammation instead of 
tolerance [193]. Also, RA has been shown to induce hypervitaminosis-A upon local 
administration [194-195], and hence it would be difficult to use this combination (cytokines + 
RA) to induce Treg in vivo. Another small molecule that synergizes with IL-2 and TGF-β to 
induce FoxP3 expression in naïve T cells is rapamycin (rapa) [196-198]. Although it has been 
demonstrated that like RA, rapa can induce Treg even in the presence of IL-6 [196], the in vitro 
phenotype and functional capabilities of rapa induced Treg (rapa-iTreg) are yet to be 
characterized.  
In this study we compare and contrast the phenotype (expression of canonical Treg 
markers and migratory surface markers), functional capabilities and stability upon in vitro re-
stimulation of TGFβ-iTreg, RA-iTreg and rapa-iTreg. Our data suggests that the combination of 
IL-2, TGF-β and rapa is capable of inducing functional and stable Treg populations with largely 
a lymphoid tissue homing capacity.  In addition, we describe the in vitro characteristics of Treg 
generated by combining IL-2, TGF-β, RA and rapa (RA+rapa-iTreg). 
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4.2 METHODS  
4.2.1 Animals 
Six-eight week old C57Bl/6 and B6.SJL-Ptprca/BoyAiTac (CD45.1) were purchased from 
Taconic and used within one month. B6(Cg)-Tyrc-2J/J (albino C57Bl/6 mice) were purchased 
from Jackson Laboratories. C57Bl/6.Luc+ mice were a kind gift from Dr. Stephen Thorne (Dept. 
of Surgery, University of Pittsburgh). All animals were maintained under specific pathogen free 
conditions. Experiments were conducted in accordance with the National Institutes of Health 
Guide for Care and Use for Laboratory Animals and under Institutional Animal Care and Use 
Committee-approved protocols. 
4.2.2 Materials 
Mouse CD4 negative isolation kit, αCD3/αCD28 labeled beads (aAPC Dynal ®) and Vybrant 
CFDA-SE cell tracer kit were from Invitrogen Corporation (Carlsbad, CA, USA). Recombinant 
mouse IL-2 (R&D systems, Minneapolis, MN, USA), recombinant human TGF-β1 (CHO cell 
derived, PeproTech, Rocky Hills, NJ, USA), all-trans-retinoic acid (Sigma, St. Louis, MO, 
USA), and rapamycin was from LC labs (Woburn, MA, USA). The following antibodies were 
purchased from eBioscience (San Diego, CA, USA): CD4 (L3T4), FoxP3 (FJK-16s), CD45.1 
(A20), CD103 (2E7), CD25 (PC61.5), GITR (DTA-1), FR4 (eBio12A5), CCR7 (4B12) and 
CCR9 (eBioCW-1.2). CTLA4 (UC10-4B9) was from BioLegend (San Diego, CA, USA). Anti-
PE microbeads were obtained from Miltenyi Biotec (Auburn, CA, USA). 
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4.2.3 T cell isolation 
Spleen and lymph nodes were dissected from mice, and single cell suspensions were prepared 
using mechanical digestion. Following RBC lysis, CD4+ cell isolation was performed using the 
CD4 negative isolation kit (Invitrogen) as per manufacturer’s instructions. To enrich for CD25- 
cells, CD4+ cells were incubated with anti-mouse CD25-PE antibody (eBioscience) followed by 
addition of anti-PE microbeads (Miltenyi). Bead-bound CD25+ cells were isolated by passing 
cells through a magnetic column. Unbound CD4+ CD25- cells were separated and used further to 
induce regulatory T cells (Treg). 
4.2.4 Treg Induction 
Freshly isolated naïve CD4+ CD25- cells were cultured with aAPC Dynal ® beads at a 2:1 
(dynal:cell) ratio in the presence of 10 ng/ml IL-2, 20 ng/ml TGF-β1 and/or 3 ng/ml (10nM) all-
trans-retinoic acid (RA) and/or 10 ng/ml rapamycin (rapa). To obtain effector T cells (Teff), 
CD4+ CD25- cells were cultured with aAPC Dynal ® beads and 10 ng/ml IL-2 only. Cell cultures 
were carried on for 4 days, and cells were subsequently separated from the magnetic Dynal® 
beads. To determine induction of Treg phenotype, FoxP3 staining and flow cytometry (BD-
LSRII) was performed at the end of the 4-day culture period as per manufacturer’s instructions 
(eBioscience). 
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4.2.5 In vitro suppression assay 
Freshly isolated naïve CD4+ CD45.1+ cells were stained with CFSE (invitrogen, as per 
manufacturer’s instructions) and co-cultured with induced Treg (generated as described above) at 
different ratios in 96-well plates. The number of naïve CD4+ CD45.1+ cells was always kept 
constant at 50,000 cells / well. For stimulation, 25,000 aAPC Dynal ® beads per well were used 
(2:1, naïve cell:dynal ratio). Co-cultures were carried out for 4 days, followed by staining for 
flow cytomtery. 
4.2.6 In vivo suppression assay:  
A modified version of the colitis model [199] was used for the in vivo suppression assays. 
Briefly, 100,000 freshly isolated naïve CD4+ CD25- cells were co-transferred with 50,000 iTreg 
(generated under different conditions from CD45.1+ mice) (naïve:iTreg) in 200 µl PBS per 
animal (in immune-deficient RAG-/- mice) through the tail vein. The mice were weighed 
regularly and monitored for any adverse signs of disease.  At 22-days post cell injection, mice 
were euthanized and the spleen, mesenteric lymph nodes and colon collected for analysis. 
4.2.7 Testing iTreg stability in vitro 
iTreg generated under different conditions and effector T cells (Teff, generated by stimulating 
naïve T cells in the presence of IL-2 only) were obtained from 4 day cultures and rested in 10 
ng/ml IL-2 for 2 days.  Following resting, cells were cultured along with aAPC Dynal ® beads as 
stimulators: (i) for Dynal ® only (no Teff and no factors) group, 100,000 iTreg were cultured with 
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200,000 Dynal along with 10 ng/ml IL-2. (ii) for Dynal ® + Teff (no factors) group, 50,000 iTreg 
were cultured with 50,000 Teff and 100,000 Dynal along with 10 ng/ml IL-2. (iii) for Dynal ® + 
factors (no Teff) group, 100,000 iTreg were cultured with 200,000 Dynal and respective factors at 
concentrations described above. (iv) for Dynal ® + Teff + factors group, 50,000 iTreg were 
cultured with 50,000 Teff and 100,000 Dynal and respective factors. Re-stimulation experiments 
were carried out for 4 days and cells were subsequently stained and analyzed by flow cytometry. 
4.2.8 In vivo migration experiments 
iTreg generated from naïve CD45.1+ CD4+ CD25- cells were injected in CD45.2 mice at a 
concentration of 2 million cells in 200 µl PBS per animal (tail vein). Three days following 
injection, mice were euthanized and the spleen, cervical lymph nodes and mesenteric lymph 
nodes collected. Single cell suspensions from each of these tissues were prepared, stained for 
different markers and analyzed by flow cytometry. For the in vivo live animal imaging 
experiments, iTreg were generated from C57Bl/6.Luc+ mice and injected in albino C57Bl/6 mice 
at a concentration of 1 million cells in 200 µl PBS per animal (tail vein). At defined time-points, 
mice were injected with 200 µl luciferin (30 mg/ml) and imaged using the IVIS 200 (Xenogen 
VivoVision, Caliper Life Sciences, Hopkinton, MA, USA). Luminescent images were analyzed 
and quantified using Igor Pro Living Image® 2.60.1 (Caliper Life Sciences). 
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4.2.9 Statistical Analysis 
Mean ± standard deviation values are reported in all figures unless otherwise indicated. Error 
bars in graphs represent standard deviations. A paired or unpaired Student’s ‘t’ test was used for 
statistical comparison between any 2 given samples unless otherwise indicated. 
4.3 RESULTS: 
4.3.1 Small molecules enhance ability of TGF-β to induce and maintain functional Treg 
Consistent with prior studies, we observed that the presence of either RA or rapa enhances the 
ability of IL-2 and TGF-β to induce FoxP3 expression in naïve T cells (Figure 14A, 14B and 15) 
[189-190, 197-198]. The same effect was observed when cells are cultured in the presence of a 
combination of IL-2, TGF-β, RA and rapa. Cells cultured under all these different conditions 
also expressed canonical Treg markers such as, FR4, CTLA4, GITR and CD25 (Figure 14C), 
suggesting that these cells are induced Treg (iTreg). Interestingly, the expression level of one of 
these markers, FR4 (which along with CD25 has been identified as markers that can help 
distinguish activated effector T cells from Treg [121]), was significantly greater in rapa-iTreg 
and RA+rapa-iTreg when compared to RA-iTreg (Figure 16). 
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Figure 14: RA and rapa enhance TGFβ’s capability to induce Treg phenotype. 
A - flow cytometry density plots indicating % of CD4+ cells that express FoxP3 (representative of 6 independent 
experiments). Plots were generated after gating on CD4+ cells. B – Quantitative analysis of the % of CD4+ that 
express FoxP3. * indicates p<0.05, and ** indicates p<0.01 when specified group was compared to the TGFβ-iTreg 
group using the paired Student’s ‘t’ test (based on n≥6). C – Representative histograms (at least 2 independent 
experiments) for canonical markers expressed on Treg. Plots were generated after gating on CD4+ FoxP3+ cells. 
Numbers on plots represent median fluorescent intensities. Filled gray histograms represent isotypes. 
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Figure 15: Ability of RA and rapa to induce Treg in combination with TGF-β is dose dependant. 
Tabulated numbers represent % of CD4+ that express FoxP3. Boxes highlighted in red (represent 
concentrations at which the best FoxP3 induction and Treg proliferation was observed) indicate the 
concentrations of TGF-β, RA and rapa used in all experiments described in the study. 
 
 
 
Figure 16: Rapa enhances induction of FR4 expression. 
Quantitative analysis of FR4 expression on iTreg generated under different conditions. Median 
fluorescence intensity (MFI) was determined after gating on the CD4+ FoxP3+ population. MFI 
values were normalized to TGFβ-iTreg FR4 expression. ** indicates p<0.01 when specified group 
was compared to the RA-iTreg group. 
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Figure 17: iTreg suppress in vitro naïve T cell proliferation. 
Treg capability of suppression determined using the CFSE dilution assay. Filled histograms (gray) represent the 
proliferation capacity of naïve T cells only (in the presence of stimulation). Black lines represent the proliferation of 
naïve T cells in the presence of iTreg under specified conditions. Ratios on the top indicate the ratio of Treg to naïve 
T cells. Plots are representative of at least 2 independent experiments.  
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In order to determine the functional capacity of the iTreg, their ability to suppress in vitro 
naïve T cell proliferation and in vivo function was tested. Upon co-culture with naïve T cells 
under in vitro stimulation (αCD3/αCD28 labeled Dynal ® beads), iTreg generated under all the 
different conditions were effective at suppressing naïve T cell proliferation (Figure 17). 
 
 
 
Figure 18: iTreg suppress in vivo naïve T cell activity. 
iTreg ability to suppress naïve T cells (Tn) in vivo determined as a measure of the development of colitis. 
Injection of naïve T cells only induced dramatic weight loss in mice while the presence of iTreg prevented 
this weight loss. Cells were injected at a ratio of 2:1 (naïve T cells to iTreg). * indicates p < 0.005 when Tn 
only group is compared to any of the iTreg injected groups (n≥3 mice / group till day 25). n ≥2 mice / 
group after day 25 
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CD4+ CD25- (naïve) T cells developed severe colitis with rapid weight loss, while mice that 
received naïve T cells along with iTreg generated under any of the aforementioned conditions (at 
2:1 ratio) were protected from the disease and loss of weight (Figure 18). 
4.3.2 iTreg stability upon re-stimulation 
It has been demonstrated that following long-term in vitro culture, there is a considerable 
reduction in the percentage of TGFβ-iTreg cells that express FoxP3 [128]. To determine if the 
same would be true with iTreg generated in the presence of RA and/or rapa, these induced 
populations were re-stimulated through TCR activation (Dynal®) with IL-2 (no addition of TGF-
β, RA or rapa) in either the absence or presence of effector T cells (Teff). Re-stimulation in the 
absence of Teff led to slightly lowered percentages of FoxP3 expressing cells among the iTreg, 
while the presence of Teff led to a marked decrease in FoxP3 expressing cells (Figure 19A). 
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Figure 19: iTreg generated in the presence of RA and/or rapa are more stable than TGFβ-iTreg in long term 
in vitro cultures. 
Quantitative analysis of the fold change in % of iTreg that express FoxP3 after in vitro re-stimulation either in the 
absence of factors (A); and the presence of factors (B). Factors indicate the cytokines and/or small molecules used to 
generate the iTreg. Data are representative of 4 independent experiments. Fold change is expressed as a ratio 
between the % of FoxP3 expressing cells at the end of the re-stimulation cultures to the % of FoxP3 expressing cells 
at the beginning of the cultures. 
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expressing cells (Figure 19B). A dramatic decrease in the percentage of cells expressing FoxP3 
was observed in TGFβ-iTreg cultured under any of the aforementioned stimulatory conditions. 
4.3.3 Expression of migratory receptors on iTreg 
RA-iTreg are known to express surface markers specifically associated with migration to the 
mucosal tissues such as CCR9 and CD103 [189-190]. We observed that rapa-iTreg do not 
express either of these markers, but express significantly higher levels of CCR7 (Figure 20A and 
20B) when compared to RA-iTreg. Interestingly, RA+rapa-iTreg, which also express 
significantly higher levels of CCR7, appear to contain two distinct iTreg populations; a CCR9+ 
CD103+ and a CCR9- CD103- population (Figure 21).  
In order to determine if the expression of these receptors would determine in vivo 
homing, iTreg generated from CD45.1 mice were adoptively transferred to healthy CD45.2 mice 
maintained under homeostatic conditions. As expected, 3 days following adoptive transfers, a 
significantly greater number of rapa-iTreg and RA+rapa-iTreg were observed in the cervical and 
mesenteric lymph nodes when compared to TGFβ-iTreg and RA-iTreg (Figure 22).  
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Figure 20: Differential expression of migratory receptors on iTreg generated under different conditions. 
A – Histograms depicting expression patterns of different migratory receptors; plotted after gating on CD4+ FoxP3+ 
cells. Numbers on plot represent MFI values. B – Quantitative analysis of CCR7 expression on iTreg generated 
under different conditions (MFI values were normalized to TGFβ-iTreg cells). * indicates p<0.05 (paired Student’s 
‘t’ test) when comparing specified group to RA-iTreg group; n=5.    
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Figure 21: Analysis of surface proteins responsible for migration of T cells to peripheral tissues. 
Density plots (flow cytometry) show that presence of RA induces expression of CCR9 on iTreg, while rapa 
reduces expression of CD103 and CCR9. The RA+rapa-iTreg appear to have two distinct population of cells; one 
that is CCR9+CD103+ and another that is CCR9-CD103-. 
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Figure 22: Differential migration pattern of iTreg generated under different conditions. 
iTreg generated from CD45.1+ were injected into CD45.2+ mice, and after 3 days Spl (spleen), 
C-Ln (cervical lymph nodes) and M-Ln (mesenteric lymph nodes) harvested to analyze the 
percentage of CD45.1+ cells. * indicates p<0.05 when comparing specified group to either the 
TGFβ-iTreg  or RA-iTreg groups. 
 
Furthermore, we observed that all adoptively transferred iTreg populations maintain their FoxP3 
expression capacity (Figure 23). The increased presence of rapa-iTreg in secondary lymphoid 
organs, and presence of RA-iTreg primarily in the gut, was confirmed using live animal imaging 
that permits the tracking of cell movement over an extended time-period (Figure 24A and 24B). 
Additionally, this data suggest that RA+rapa-iTreg migrate both to the secondary lymphoid 
organs and the gut tissue, although there are considerably greater numbers of cells in the gut 
tissue (which might be due to the inclusion of mesenteric lymph nodes among the gut tissue in 
these live animal images). 
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Figure 23: iTreg maintain FoxP3 expression following injection in mice maintained under homeostatic 
conditions. 
Analysis of FoxP3 expression on CD45.1+ cells that were injected in wild type CD45.2+ mice. Spl indicates spleen, 
C-Ln indicated cervical lymph nodes and M-Ln indicates mesenteric lymph nodes. 
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Figure 24: Live animal imaging shows areas of iTreg localization upon injection in vivo. 
A – Representative images acquired using the IVIS 200, showing iTreg localization over 10 days. Red ellipses 
indicate the cervical lymph node and gut area. B – A ratio of the average luminescence measurements obtained from 
the red ellipses depicted as a function of time. * indicates p≤0.05 when comparing rapa-iTreg with RA-iTreg and # 
indicates p≤0.05 when comparing rapa-iTreg with RA+rapa-iTreg. n≥3 mice for all groups. C-Ln indicates the 
cervical lymph node area. 
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4.4 DISCUSSION 
Treg can be induced under a variety of different in vitro [189-190, 196-197, 200] and in vivo [88, 
192, 201-202] conditions. Treg induced under different conditions have been reported to have 
unique characteristics that distinguish them from each other and from naturally occurring Treg. 
Identification of these unique characteristics provides us insight into their potential to be used in 
treating inflammatory disorders (such as autoimmunity and allergies) and transplant rejection, or 
in preventing tumor growth and metastasis [129]. For example, it has been demonstrated that RA 
can help to convert naïve T cells to Treg. These RA-iTreg are stable under inflammatory 
conditions and have the potential to prevent inflammation in the gut primarily due to their ability 
to specifically migrate to these tissues. However, gut homing specificity could potentially be a 
hindrance to using these cells to treat autoimmunity or transplant rejection at other peripheral 
sites. 
In this study in vitro generated rapa-iTreg were directly compared TGFβ-iTreg, RA-iTreg 
and RA+rapa-iTreg. In many aspects, such as expression of canonical Treg markers (Figure 14), 
in vitro and in vivo suppressive capabilities these different iTreg appear to be similar (Figure 17 
and 18). However, some noticeable differences between these iTreg were identified. For 
example, the expression of one of the canonical surface markers, FR4, was significantly greater 
on the surface of rapa-iTreg and RA+rapa-iTreg when compared to the RA-iTreg (Figure 14 and 
16). It has been suggested that expression of this folate receptor may allow for greater 
survivability and long-term stability of Treg populations in the periphery [121], and it remains to 
be determined if this is the case with rapa-iTreg and RA+rapa-iTreg. 
Most importantly, key differences in the expression of certain chemokine receptors and 
integrins on the surface of RA-iTreg, rapa-iTreg and RA+rapa-iTreg were observed. As 
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demonstrated previously, CCR9 and CD103 (surface proteins that direct migration of cells 
towards the small intestine lamina propria and the epithelium respectively) expression was 
upregulated on RA-iTreg (Figure 20A). Rapa-iTreg do not express either of these surface 
proteins, but express the lymphoid organ homing receptor CCR7 at significantly greater levels 
(Figure 20B). This pattern of expression correlates well with their in vivo lymphoid organ 
homing capacity of rapa-iTreg, while the RA-iTreg primarily migrate to the gut tissue (Figure 22 
and 24). RA+rapa-iTreg also express higher levels of CCR7 (Figure 20B), but present as a 
bimodal distribution of cells, where some cells are CCR9+ CD103+ and others are CCR9- CD103- 
(Figure 23). This bimodal population could suggest that cells affected by RA are not influenced 
by rapa and vice versa. It remains to be seen if such an expression pattern allows for the 
RA+rapa-iTreg to be more efficient at suppressing immune responses (due to their ability to 
simultaneously migrate to both mucosal tissues and lymphoid organs) in vivo, and if such an 
effect cannot be observed by using a mixture of RA-iTreg and rapa-iTreg. 
Additionally, it was observed that although RA and/or rapa induced Treg are more stable 
when compared conventional TGFβ-iTreg upon re-stimulation, they tend to lose their FoxP3 
expression in the presence of stimulation and effector T cells (an in vitro mimic of inflammatory 
conditions). This loss of FoxP3 expression is limited to the presence of effector T cells (Teff) as 
in the presence of mature dendritic cells such an effect was not observed (data not shown). 
Nevertheless, the inflammatory effect of Teff is negated in the presence of an immunosuppressive 
milieu (such as the combination of IL-2, TGF-β, and RA or rapa) and the iTreg maintain their 
FoxP3 expression even after incubation with Teff (Figure 19). This would suggest that the use of 
Treg induced in the presence of small molecules might be limited to situations where an 
immunosuppressive milieu can be established using (for example) low dose immunosuppressive 
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regimens, or controlled release formulations for immunomodulatory agents. Furthermore, 
recently it has been suggested that the methylation patterns on the Foxp3 gene locus is a good 
determinant of long-term Treg stability [128]. It remains to be determined if these iTreg differ in 
this aspect.  
Finally, given the difficulties and cost associated with cellular therapies, a system capable 
of inducing Treg in vivo would be ideally suited for treating autoimmunity and transplant 
rejection. To this end, it would be necessary to use formulations that deliver a combination of 
Treg inducing factors in a local and sustained fashion in vivo, which can be achieved using 
controlled release formulations that have been developed in the past [156, 203]. The preferred 
combination of factors to be used in vivo might be IL-2, TGF-β, and rapa, as (i) rapa is currently 
approved for use clinically, (ii) rapa has the ability to suppress a variety of immune functions 
apart from inducing Treg, and (iii) rapa might be safer than RA, given the latter’s ability to 
induce hypervitaminosis A. 
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5.0  CONTROLLED RELEASE FORMULATIONS FOR INDUCING REGULATORY 
T CELLS 
5.1 INTRODUCTION 
 
As discussed in Chapter 1 (Section 1.10), increased presence of Treg has been suggested to have 
positive outcomes in autoimmunity [126, 204], transplant rejection [178, 183] and inflammatory 
diseases such as dermatitis [205], psoriasis [206-207] and periodontitis [208-209]. Given this 
evidence, it is not hard to perceive that strategies to boost local Treg numbers could be 
developed into potential therapeutics to treat these diseases.  
Enhancing numbers of Treg at local tissue sites can be achieved by (i) ex vivo expansion 
of Treg followed by their local administration or systemic re-infusion, or (ii) in vivo 
manipulation of immune cells in order to tip the balance between Treg and effector T cells 
towards Treg. The latter approach is preferable given the stringency associated with ex vivo 
culture of human cells under Good Manufacturing Practice (GMP) conditions [138, 140, 184]. 
One possible means to achieve increased number of Treg in vivo is the use of biologic therapies 
that selectively enhance Treg numbers and function. Various antibodies (Abs), such as anti- IL-2 
monoclonal (m) Ab [210], superagonistic anti-CD28 antibody [211], and agonistic anti-CD4 
antibody [212], have been used in the past to increase in vivo Treg numbers. However, their 
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exact mechanism of action has still not been characterized, and their safety in humans remains 
questionable. In fact, phase I clinical trials of the superagonistic anti-CD28 Ab (TGN1412) 
resulted in severe negative reactions (cytokine ‘storm’) in all 6 human subjects who received the 
Ab [213]. 
An alternative approach to increase Treg numbers in vivo is through the establishment of 
a local immunosuppressive environment that selectively favors Treg expansion. In Chapter 4 we 
provide evidence that an environment rich in IL-2, transforming growth factor- β1 (TGF-β) and 
rapamycin (rapa), favors Treg development even under inflammatory conditions, as suggested by 
others [196-198]. However, providing a continuous presence of these factors in vivo, has proven 
difficult. Controlled release vehicles for these factors offer a potential solution to these problems.  
In this chapter we describe the development and testing of controlled release formulations 
for IL-2, TGF-β and rapa. We show that a combination of these formulations (called FactorMP 
henceforth) is capable of in vitro Treg induction using either mouse or human cells. Further, we 
demonstrate that the FactorMP-induced Treg maintain their proliferative capacity and functional 
capability in vitro and express phenotypic surface markers that are consistent with soluble factor 
induced Treg. 
5.2 MATERIALS AND METHODS: 
5.2.1 Mice 
Six-eight week old C57Bl/6 (B6) and B6.SJL-Ptprca/BoyAiTac (CD45.1) were 
purchased from Taconic and used within two months. All animals were maintained under 
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specific pathogen free conditions. Experiments were conducted in accordance with the National 
Institutes of Health Guide for Care and Use for Laboratory Animals and under Institutional 
Animal Care and Use Committee-approved protocols. 
 
5.2.2 Microparticle Preparation 
IL-2 and TGF-β microparticles (IL2MP and TGFβMP, respectively) were prepared using 
the double emulsion-evaporation technique, as described [156, 203]. For the IL-2MP the 
following conditions were used. Five µg of recombinant (r) mouse IL-2 (R&D Systems 
Minneapolis, MN) was mixed with 2 mg of BSA and 5 mM NaCl in 200 µl of de-ionized water. 
This solution was added to 4 ml of dichloromethane containing 200 mg of poly lactic-co-glycolic 
acid (PLGA; RG502H, Boehringer Ingelheim Chemicals Inc., Petersburg, VA), and the mixture 
was agitated using a sonicator (Vibra-Cell, Newton, CT) at 25% amplitude for 10 sec, creating 
the primary emulsion. This emulsion was then mixed with 60 ml of 2% polyvinyl-alcohol (PVA, 
MW ~25,000, 98% hydrolyzed; Polysciences) under homogenization (L4RT-A, Silverson, 
procured through Fisher Scientific) at 3000 rpm for 1 min, creating the second emulsion. The 
resulting double-emulsion was then added to 80 ml of 1% PVA, and left for 3 hr spinning at 600 
rpm. Subsequently, the microparticles were centrifuged (200g, 5 min, 4 °C), washed 4 times in 
de-ionized water, and lyophilized (Virtis Benchtop K freeze dryer, Gardiner, NY; operating at 80 
mTorr). 
For the TGFβMP the following conditions were used. One µg of r-human TGF-β (CHO 
cell-derived, PeproTech, Rocky Hill, NJ) was mixed with 10 mg D-mannitol, 1 mg of BSA, and 
15 mM NaCl in 200 µl of de-ionized water. This solution was added to 4 ml of dichloromethane 
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containing 200 mg of PLGA (RG502H), and the mixture agitated using a sonicator at 25% 
amplitude for 10 sec, creating the primary emulsion. This emulsion was then mixed with 60 ml 
of 2% PVA (containing 125 mM NaCl) under homogenization at 3000 rpm for 1 min, creating 
the second emulsion. The resulting double emulsion was then added to 80 ml of 1% PVA 
(containing 125 mM NaCl), and left for 3 hr spinning at 600 rpm. Subsequently, the 
microparticles were centrifuged (200g, 5 min, 4 °C), washed 4 times in de-ionized water, and 
lyophilized. 
The rapaMP were prepared using the single emulsion-evaporation technique as described 
[59, 214]. Briefly, 1 mg of rapa (LC labs, Woburn, MA) dissolved in DMSO was mixed with 4 
ml of dichloromethane containing 200 mg of PLGA (RG502H). This solution was mixed with 60 
ml of 2% PVA under homogenization at 3000 rpm for 1 min creating the microparticle emulsion. 
The resulting emulsion was then added to 80 ml of 1% PVA and left for 3 hours spinning at 600 
rpm. Subsequently, the microparticles were centrifuged (200g, 5 min, 4 °C), washed 4 times in 
de-ionized water, and lyophilized. 
5.2.3 Release Assays 
Release assays were conducted by incubating a suspension of particles; (i) 10 mg in 1 ml 
of media for IL-2MP and TGFβMP, and (ii) 10 mg in 1 ml of PBS (containing 0.2% Tween-80) 
for rapaMP, on a roto-shaker at 37 °C. At regular time intervals, particle suspensions were 
centrifuged (250g, 5min), the supernatant removed, and the particles re-suspended in 1 ml of 
appropriate solution. The amount of each cytokine in the supernatant was measured using a 
cytokine-specific ELISA (R&D systems, Minneapolis, MN), and the amount of rapa was 
measured using spectrophotometry (absorbance at 278 nm). 
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5.2.4 Mouse T cell isolation 
Spleen and lymph nodes were dissected from B6 or CD45.1 mice. Following mechanical 
digestion, the tissue suspension was passed through a 70 µm nylon filter to obtain a single cell 
suspension of leukocytes. Predominantly naïve CD4+ T cells were isolated from this suspension 
with a CD4+ T cell negative isolation kit (Invitrogen, Carlsbad, CA) as per the manufacturer’s 
instructions. These purified CD4+ T cells were used in cell culture and suppression assays. 
5.2.5 Induction of regulatory T cells (Treg) 
For Treg induction experiments, naïve T cells were cultured either in direct contact with 
FactorMP (in 96-well round bottom cell culture plates), or separated from FactorMP by 
permeable transwell inserts (HTS Transwell®-96, 0.4μm pore size; Corning, Lowell, MA).  
Dynabeads® mouse T-activator CD3/CD28 beads (Dynabeads®; Invitrogen, Carlsbad, CA) 
were used at a 2:1 (beads:T cells) ratio to activate T cells, and cultures maintained for 4 days. For 
cultures in the presence of soluble factors, the following concentrations of factors were used: 10 
ng/ml IL-2, 5 ng/ml TGF-β and 10 ng/ml rapa (corresponds to a total amount of 2 ng IL-2, 1 ng 
TGF-β and 2 ng rapa). The following quantities of microparticles were used for the induction 
experiments in 200 μl of cell culture media: 2 mg TGFβMP, 0.5 mg IL-2MP, and ~ 0.01 - 0.05 
mg rapaMP. To determine the phenotype of cells after culture, cells were stained with anti-CD4 
(L3T4), anti-FoxP3 (FJK-16s), anti-CD25 (PC61.5), anti-glucocorticoid-induced TNFR-induced 
protein (GITR; DTA-1), anti-folate receptor-4 (FR4; eBio12A5) (antibodies from eBiosciences, 
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San Diego, CA) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA4; UC10-4B9, from 
Biolegend, San Diego, CA). To determine iTreg proliferation, naïve T cells were stained with 
carboxyfluorescein diacetate succinimidyl ester cell tracer (CFSE; Invitrogen, Carlsbad, CA) 
prior to activation with Dynabeads®. Stained cells were then analyzed on a BD-LSRII flow 
cytometer. For suppression assays, cells (from Transwell® cultures) were collected after 4 days 
of culture and used as described below. 
5.2.6 Suppression assay 
Freshly isolated naïve CD4+CD45.1+ T cells were stained with CFSE (Invitrogen, as per 
manufacturer’s instructions) and co-cultured with induced Treg (generated as described above) at 
different ratios in 96-well plates. The number of naïve CD4+CD45.1+ cells was kept constant at 
50,000 cells / well. For stimulation, 50,000 Dynabeads® per well were used. Co-cultures were 
carried out for 4 days, after which cells were stained for flow cytometry. 
5.2.7 Human T cell culture 
CD4+ T cells were isolated from human PBMC using the CD4 negative isolation kit (Miltenyi 
Biotec, Auburn, CA). Cells (500,000) were cultured in 0.5 ml of AIM-V cell culture media 
(supplemented with serum) in the presence of human T cell activation beads (anti-CD2, anti-
CD3 and anti-CD28 coated beads, Miltenyi Biotec, Auburn, CA). Cell culture media was 
supplemented with additional factors or FactorMP at the following concentrations: 500 U/ml 
recombinant-human IL-2, 10 ng/ml TGF-β, 2 ng/ml rapa, 8 mg/ml of TGFβMP, and/or 0.02 
mg/ml of rapaMP. Following 4 days of culture, cells were collected, stained with anti-human 
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CD3 (BD Pharmingen), anti-human CD4 (L200, BD Pharmingen), anti-human CD25 (BC96, BD 
Pharmingen), anti-human FoxP3 (PCH101, BD Pharmingen) and Treg induction analyzed by 
flow cytometry. Soluble IL-2 was used in all of these cultures instead of IL-2MP, as IL-2MP 
encapsulated recombinant mouse IL-2 and not the human protein. 
 
5.3 RESULTS 
 
5.3.1 Microparticle Characterization 
IL2MP, TGFβMP, and rapaMP were all prepared under similar conditions, using the same 
polymer (PLGA, RG502H, viscosity 0.16-0.24 dl/g). Scanning electron micrographs (Figure 25, 
top panel) show that individual particles are spherical and confirm the volume average size 
distributions (IL2MP = 25.5 ± 7.5 µm; TGFβMP = 16.7 ± 6.3 µm; rapaMP = 16.7 ± 6.4 µm; 
errors indicate standard deviation from the mean for each particle set). Additionally, the images 
show that IL2MP have slightly porous exterior surfaces. These particles were specifically 
formulated to be porous (by altering osmotic pressures between the inner emulsion and the 
outside aqueous phase during microparticle preparation) so that a high initial burst followed by 
continuous release could be obtained (Figure 1, bottom panel) [159-160]. Further, we observe a 
linear release of TGF-β following a ~2 week lag phase, and a continuous release from rapaMP 
(Figure 25, bottom panel). 
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Figure 25: Microparticle Characteristics. 
Scanning electron micrographs (top panel) and in vitro release profiles (bottom panel) of IL-2, TGFβ (in cell culture 
media) and rapa (in saline containing 0.2% Tween-80). Error bars on release profiles represent standard deviation 
based on n = 6 measurements for IL-2MP and TGFβMP, and n= 3 measurements for rapaMP. 
5.3.2 Treg Induction 
Soluble IL-2, TGF-β and rapa have been shown previously to induce Treg (iTreg) [196-197]. We 
wanted to determine if degradable polymer-based formulations designed to sustain the release of 
these factors could induce Treg reliably. Indeed, we observed that the microparticle formulations 
were similar to soluble factors in their in vitro Treg induction efficacy, as measured by FoxP3 
expression (Figure 26A and 26B). In addition, the FactorMP were capable of inducing Treg by 
releasing equivalent (10-15 ng/ml IL-2 and 10-50 ng/ml rapa), or reduced (1-2 ng/ml of TGF-β) 
 
IL-2MP TGFβMP rapaMP
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total amounts of the factors over 4 days of culture. Further, we observed that iTreg were capable 
of robust proliferation (as observed through the dilution of the CFSE stain, Figure 26A). 
 
 
 
Figure 26: FactorMP induce mouse Treg. 
A – representative flow cytometry dot plots (gated on CD4-expressing cells) of naïve T cells stimulated in the 
presence of soluble factors or FactorMP. The X axis on these plots represents CFSE, which is a cell proliferation 
marker and the Y axis represents intracellular FoxP3, which is a definitive marker for mouse Treg. B – quantitative 
analysis of the percentage of CD4+ T cells that express FoxP3 after culture for 4 days under different conditions; * 
indicates p<0.05 based on n ≥ 3 independent experiments. 
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5.3.3 Phenotype and function of microparticle induced Treg phenotype 
In addition to FoxP3, Treg are known to express many other characteristic surface proteins. We 
tested for 4 canonical surface markers: CD25, FR-4 and GITR. CD25 is the high-affinity IL-2 
receptor, which increases sensitivity to IL-2 and is important for Treg proliferation. FR-4, a 
folate receptor, is required for folic acid sensing and uptake, which in turn prolongs Treg 
survival. Finally, GITR (glucocorticoid-induced TNF receptor-related protein) is a surface 
receptor that has been suggested to play an important role in Treg survival and suppression. We 
observed that FactorMP-iTreg expressed these surface markers at levels equivalent to those on 
soluble factor-iTreg (Figure 27). Importantly, although the expression of these surface proteins, 
along with FoxP3, suggests that these cells are Treg, it does not guarantee suppressive function. 
In order to test the ability of FactorMP-iTreg to suppress naïve T cell proliferation, we adopted 
an in vitro co-culture system described previously [215]. In these co-culture suppression assays, 
we observe that FactorMP-iTreg indeed possessed suppressive capabilities similar to Treg 
induced by soluble factors and natural Treg (Figure 28). 
 95 
 
 
 
Figure 27: FactorMP-iTreg express canonical Treg surface markers. 
Representative flow cytometry dot plots (gated on CD4 expressing cells) showing the expression of surface markers 
and intracellular FoxP3 on naïve T cells stimulated in the presence of soluble factors or FactorMP. 
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Figure 28: FactorMP iTreg are suppressive. 
Representative plots of CFSE dilution showing that the FactorMP-iTreg can suppress naïve T cell proliferation. 
Gates on individual plots indicate the percentage of proliferating cells. Ratios indicate the number of Treg in culture 
to the number of naïve T cells. 
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5.3.4 Microparticle formulations can induce Treg from human T cells 
Human T cells isolated from PBMC can also be induced to a Treg phenotype using soluble IL-2, 
TGF-β and rapa [216-217]. For potential clinical application of our technology, we needed to 
determine if the microparticle formulations were capable of inducing Treg from human T cells. 
To this end, human T cells were cultured in the presence of soluble factors or FactorMP. We 
observe that the microparticles were equally capable of inducing Treg when compared to the 
soluble factors, while releasing equivalent (1-10 ng/ml rapa) or reduced (2-4 ng/ml TGF-β) 
amounts of factors (Figure 29A and 29B). 
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Figure 29: Microparticle formulations can generate human-iTreg. 
A – representative plots displaying FoxP3 expression profile on human T cells cultured under different conditions. 
Numbers in plots represent the median fluorescence intensities (MFI). B – quantitative analysis of normalized 
FoxP3 MFI as determined from 2 independent experiments (n≥3). MFI was normalized by determining the ratio of 
experimental MFI and control (soluble IL-2 treated cells) MFI. 
5.4 DISCUSSION 
Therapies that enhance Treg numbers and function have the potential to cure diseases associated 
with adverse inflammation [126, 129]. Indeed, clinical trials are currently testing cellular 
therapies involving Treg as potential therapeutics for treating graft versus host disease [138]. 
However, Treg-based cellular therapies face many challenges, which include, but are not limited 
to: (i) difficulties in isolating pure and homogenous populations and large quantities of Treg 
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from the blood, (ii) inconsistent maintenance of Treg phenotype and suppressive function post-
proliferation, and (iii) the need for GMP facilities [138, 140, 184]. Hence, acellular therapies that 
can increase numbers and/or suppressive potency of Treg without the need for ex vivo culture 
could be transformative. 
One potential method to increase the ratio of Treg to effector T cells is to establish an 
environment rich in IL-2, TGF-β and rapa as described [196-198]. Such an immunosuppressive, 
Treg-inducing environment can be attained through the sustained release of these factors at a 
local site. To that end, release formulations were fabricated using an FDA approved, widely used 
polymer, PLGA. These formulations were specifically prepared to ensure that the release profiles 
fit our needs for the induction and proliferation of Treg. For example, IL-2 is required for Treg 
survival, and it has been suggested high initial doses might help Treg grow better and resist 
apoptosis [218-219]. Hence, we prepared slightly porous IL2MP that have a high initial burst 
followed by a slow continuous release of the factor over a 5 week time frame (Figure 25). We 
also needed a continuous release formulation for TGF-β, which has not been fabricated 
previously. Accordingly, we prepared new TGF-β formulations capable of linear release over a 3 
week period (Figure 25) beginning after a 2 week lag phase. Although this 2 week initial lag 
phase was unexpected, unpublished data (Hwang M.P. et. al., manuscript in preparation) from 
our lab suggests that the initial lag phase could be due to ionic interactions between TGF-β and 
PLGA.  This ionic interaction could be a result of the high isoelectric point (pI) of TGF-β and the 
relatively low pH conditions inside the microparticles. Regardless, to overcome the problem of 
the initial lag phase we simply pre-incubated the TGFβMP (18-22 days) prior to use in cell 
culture. Finally, rapaMP were also formulated to be similar in size to the IL2MP and TGFβMP 
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and release continuously over a 2-3 week time frame as previously demonstrated (Figure 25) [59, 
214]. 
Importantly, the combination of these microparticle formulations (FactorMP) appears to 
be as effective as soluble factors at inducing Treg from naïve T cells in in vitro cultures. 
Additionally, we determined that the FactorMP iTreg were capable of robust proliferation 
(Figure 26), expressed canonical surface markers representative of Treg (Figure 27), and were 
able to suppress naïve T cell proliferation in an in vitro suppression assay (Figure 28). Further, it 
was observed that Treg induction and proliferation occurred even when the cells were in contact 
with microparticles, suggesting that the microparticles do not have any adverse on these cells. 
Finally, we observed that these microparticles are equally effective at inducing human Treg. The 
human-iTreg showed high expression of FoxP3 and were also capable of proliferation (Figure 
29).  Overall, our data suggests that these FactorMP have the potential to be used in vivo for local 
Treg induction at sites of transplant rejection or autoimmunity. 
We envisage these particulate formulations could be used as an ‘off-the-shelf’ therapeutic 
for creating an immunosuppressive environment and increasing the presence of Treg at sites of 
inflammation. We are currently testing these particles in in vivo mouse models of contact 
dermatitis and periodontitis, diseases where immune homeostasis is lost and needs to be restored. 
Another possible application for such formulations would be skin and composite tissue 
transplantation, where a local immunosuppressive environment could prevent graft rejection 
while retaining the integrity of the systemic immune system that can continue to fight infections 
and inhibit malignancies. 
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6.0  CONCLUSIONS AND FUTURE WORK 
 
Synthetic systems that modulate regulatory immune responses in vivo hold tremendous potential 
for the treatment of autoimmunity, transplant rejection and other inflammatory diseases such as 
periodontitis and dermatitis. We describe three different degradable and biocompatible 
controlled release formulations that can possibly be used to modulate the immune system in vivo.  
One of the formulations involves delivery of immuno-modulatory agents to DC. 
Immunosuppressive drugs such as rapa are capable of altering DC function [30-32], and our data 
shows that intracellular DC-specific delivery of rapa using controlled release formulations 
(rapaMP) can generate suppressive DC that are significantly better than soluble rapa-treated DC 
at suppressing T cell proliferation (Chapter 2). This altered DC function could possibly be due to 
the greatly lowered expression of co-stimulatory proteins on the surface of DC that have 
internalized rapaMP. A system capable of DC-specific delivery of immunosuppressive agents 
can potentially be used to suppress the stimulatory functions of DC in inflammatory bowel 
disease, type I diabetes and even skin transplant rejection. 
The second formulation described here is based on mimicking a strategy employed by 
tumors to evade the immune system. Tumors and tumor-associated cells are known to secrete a 
chemokine, CCL22, for the recruitment of regulatory T cells (Treg) and consequent evasion of 
immune responses [173-174]. We synthesized a continuous and sustained release formulation of 
 102 
CCL22 using PLGA microparticles (CCL22MP), to mimic tumor cells. We show that CCL22MP 
are capable of recruiting Treg using a new, non-invasive in vivo migration assay (Chapter 3). 
Additionally, injection of CCL22MP at sites of cell (allogeneic LLC transplant studies) or 
composite tissue (alogeneic whole limb transplant studies) transplants leads to a considerable 
delay in rejection of the graft, suggesting the potential of these formulations to be used to treat 
transplant rejection as well as autoimmunity. 
Further, we have thoroughly characterized a combination of factors that can induce Treg 
from naïve T cells and help to establish a local immunosuppressive environment in vivo. 
Previously, the combination of IL-2, TGF-β and all-trans retinoic acid (RA) and a combination 
of IL-2, TGF-β and rapa have shown to induce Treg (iTreg) in vitro [189-190, 196-197]. While 
the phenotype and functional capabilities of iTreg generated in the presence of IL-2, TGF-β and 
RA (RA-iTreg) have been thoroughly characterized, the characteristics of iTreg generated in the 
presence of IL-2, TGF-β and rapa (rapa-iTreg) are yet to be determined. Our studies show that 
rapa-iTreg do not differ from RA-iTreg in their in vitro and in vivo suppressive capabilities and 
appear to be stable under long-term culture conditions in vitro. However, a major difference 
between these iTreg was their in vivo migratory capacity, with rapa-iTreg retaining the capacity 
to migrate to lymphoid tissues throughout the body, while RA-iTreg migrated primarily to the 
gut (Chapter 4). Given this observation and the fact that rapa helps to maintain a suppressive 
environment (while RA need not), we chose the combination of IL-2, TGF-β and rapa to 
fabricate controlled release vehicles that can potentially be used in vivo. We show that controlled 
release formulations of this combination of agents (FactorMP) can induce and promote Treg 
proliferation from both mouse and human naïve T cells (Chapter 5). 
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Finally, the synthetic systems developed herein, may be used individually or in 
combination to modulate immune responses in vivo, with potential applications in treating 
autoimmunity and transplant rejection. Furthermore, these systems are specifically designed as 
modular platforms that can easily be modified to incorporate a protein or drug of choice, for the 
development of novel therapeutics as well as a tool to study cellular responses in vitro and in 
vivo. 
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APPENDIX A 
CCL22MP IN COMPOSITE TISSUE TRANSPLANTATION 
In chapter 3, we demonstrate that CCL22MP are capable of recruiting Treg in vivo and delaying 
rejection of allogeneic cellular transplants. Next, we wanted to determine if CCL22MP could 
prolong graft survival in a clinically relevant model for transplantation. Whole limb 
transplantation in rats has previously been established as a good pre-clinical model for composite 
tissue transplantation [220-221]. In this section, we test the ability of CCL22MP to delay graft 
rejection in this pre-clinical model of transplantation. 
A.1 METHODS 
Whole limb transplants were performed as described (Figure 30) [220-221]. Briefly, the hind 
limbs of Brown-Norway rats were transplanted to Lewis rats (completely mismatched tissue). 
Four days prior and 1 day post transplantation the host rats received anti-lymphocyte serum 
treatment. On the day of transplantation, the rats received a sub-cutaneous injection of 20 mg of 
CCL22MP (or BlankMP as control). Following transplantation, the host rats received 0.5 mg/kg 
FK506 daily for 20 days. On day 18 post transplantation, a second dose of CCL22MP was 
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injected sub-cutaneously in one treatment group. The transplants were monitored daily for signs 
of rejection as described [222]. 
 
 
Figure 30: Composite tissue transplantation in rats. 
A – cartoon depicting the use of CCL22MP in an allogeneic whole limb transplant model. B – schematic describing 
the immunosuppressive regimen used to delay graft rejection. ALS indicates anti-lymphocyte serum , FK indicates 
FK-506 (tacrolimus), BN indicates Brown Norway rats and LEW indicates Lewis rats. 
A.2 RESULTS AND DISCUSSION 
Hautz et.al. [222] have demonstrated that cessation of systemic immunosuppression leads to 
rapid rejection of the transplanted limb. We observe the same in our experiments, where all but 
one of the BlankMP treated transplants rejected by day 50 post transplantation (systemic FK506 
treatment was stopped at day 20 post transplantation as described in Figure 30). We observe that 
ALS 
(day -4 
and 1)
0
CCL22MP
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BN   Lew
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B
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a single dose of CCL22MP does not prolong transplant survival with all the transplants rejecting 
within 50 days post transplantation. However, transplants that received the double dose of 
CCL22MP show enhanced survival rates (p = 0.1) with 2 out of 13 transplants surviving over 
day 100 (Figure 31A). Additionally, we observe that most of the CCL22MP (double dose) 
treated transplants have an intact epidermal layer with low infiltration of mono-nuclear cells, 
while a majority of the BlankMP treated transplants have very high infiltration of mono-nuclear 
cells and show loss of the epidermal layer 25 days post transplant (Figure 31B).  
Currently, additional transplant experiments are underway to determine the dosing 
schedule and the concentration of CCL22MP required for observing significant differences in 
transplant survival rates. This preliminary study demonstrates the promise of CCL22MP in 
delaying transplant rejection, and its potential for translation to the clinic. 
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Figure 31: CCL22MP can delay composite tissue graft rejection. 
A – survival curves illustrating that the double dose of CCL22MP is better at delaying transplant rejection when 
compared to the control and single CCL22MP dose groups (p ~ 0.1). B – hematoxylin and eosin staining of skin 
biopsies from  the transplanted hind limb 25 days post transplantation. White arrows point to the epidermal layer, 
which is present in the CCL22MP (double dose) injected group but absent in the BlankMP group. 
BlankMP
CCL22MP
A B
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APPENDIX B 
SURFACE LABELING OF PLGA MICROPARTICLES WITH ANTI-CD3/ANTI-CD28 
TO MIMIC DC FUNCTION 
As discussed in chapter 1, the primary function of DC is to activate naïve T cells through antigen 
presentation (Signal 1) and co-stimulation (Signal 2), which is achieved through surface 
receptor-receptor interaction. Synthetic systems that hope to mimic DC function must be able to 
replicate this function reliably. The first completely artificial DC systems developed specifically 
for the purpose of activating and expanding naïve T cells was the Dynabeads® technology (from 
Dynal Biotech., now a part of Life Technologies). In this system, magnetic epoxy beads are 
labeled on the surface with antibodies against CD3 and CD28 (receptors that are part of the TCR 
and co-stimulatory apparatus on T cells, respectively). Although this system can successfully 
activate and expand naïve T cells in vitro, it cannot be used in vivo as the beads are made of a 
non-degradable, non-biocompatible material. A possible solution to this problem is to replace the 
epoxy beads with degradable, biocompatible particles like those made of PLGA. Herein, we 
describe a strategy for labeling the surface of PLGA microparticles with antibodies for naïve T 
cell stimulation. 
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B.1 PROTOCOL FOR LABELING THE SURFACE OF PLGA PARTICLES 
Labeling of the surface of PLGA particles is achieved by covalently linking free amine groups 
on the streptavidin to the free COOH (end groups on the polymer) groups on the surface of 
particles, followed by the addition of biotinylated antibodies (as a free COOH group is required 
on the surface, particles fabricated with end-capped polymers cannot be labeled using this 
procedure). 
  
i. Weigh out 10 mg of PLGA particles in 1.5 ml Lo-Bind Eppendorf tubes. 
ii. Wash particles with 1 ml of bicarbonate buffer (pH 9.6-9.8) – twice. 
iii. Wash particles with 1 ml of MES buffer (pH 6) – twice. 
iv. Add 4mM EDC (Acros) and 5mM sulfo-NHS (Pierce). This can be done as below – 
a. Make up a 1.91 mg/ml solution of EDC in MES buffer. Add 400 ul of this to 
particles 
b. Make up a 2.17 mg/ml solution of sulfo-NHS in MES buffer and add 500 ul of 
this. 
c. This can be scaled up depending on the number of particle sets. 
v. Make up the final volume to 1 ml using MES buffer and to control groups do not add 
these chemicals (add only 1 ml of MES buffer). 
vi. Allow for chemical reaction to take place for 1 hour on roto-shaker at room temperature. 
vii. Wash particles once with DPBS. 
viii. Add 100 ul of streptavidin solution (1 mg/ml stock) and make up final volume to 1 ml 
using DPBS. 
ix. Allow to react for 4 hours on roto-shaker at room temperature. 
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x. Wash 2 times with DPBS. 
xi. Wash once with 1% BSA prepared in DPBS. 
xii. Add 1 ml of DPBS to particles, followed by appropriate amounts of anti-CD3 and anti-
CD28 (amounts depend on the size of the particles and depends on the ratio of the 2 
antibodies desired). 
xiii. Allow to react for 90 min at room temperature on roto-shaker. 
xiv. Wash 3 times with DPBS. 
xv. Wash once with D.I. water 
xvi. Add 100 ul of D.I. water and freeze dry for 48 hours. 
 
Solutions and reagents required: 
i. Bicarbonate Buffer (pH 9.6-9.8): Add 1.68 grams of Sodium Bicarbonate to 400 ml of 
D.I. water, followed by 1 ml of 4N NaOH. The resultant solution is biocarbonate buffer 
at a pH of around 9.6-9.8. 
ii. MES buffer (pH 6): Add 9.76 grams of MES (2-(N-morpholino) ethanesulphonic acid) 
to 450 ml of D.I. water. Adjust pH to 6 with 4N NaOH, and make up volume to 500 ml 
final. 
iii. EDC and NHS solutions – make as suggested above. 
iv. DPBS – Phosphate buffered saline from Invitrogen 
v. Streptavidin solution – Dissolve 1 mg of Streptavidin (Promega) in 1 ml of DPBS. Make 
200 ul aliquots and freeze. Add 100 ul of this to each particle set. 
vi. 1% BSA – Add 1gram of BSA to 100 ml of DPBS to prepare a 1% BSA solution. Scale 
down to appropriate amounts for small experiments. 
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B.2 RESULTS  
PLGA microparticles (15-20 µm avg. diameter) were labeled with anti-CD3 (biotin) and anti-
CD28 (biotin) using the aforementioned procedure. Thymidine incorporation and CFSE dilution 
assays (a measure of T cell proliferation) showed that anti-CD3 and anti-CD28 labeled 
microparticles (aAPC) were capable of activating naïve T cells (Figure 32). Additionally, we 
observe that a ratio of 2:1 (anti-CD3:anti-CD28) as well a concentration of 4 µg of anti-CD3 
worked the best at enabling T cell proliferation (Figure 33). 
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Figure 32: anti-CD3/anti-CD28 labeled particles can function as artificial antigen presenting cells (aAPC). 
The ability of dynal ® (positive control) beads and PLGA microparticles (aAPC and negative controls)  in 
proliferating naïve T cells as measured using the thymidine incorporation assay (A) and the CFSE dilution assay 
(B). Control Strept. refers to microparticles labeled with streptavidin and antibodies in the absence of EDC and NHS 
(see protocol for labeling). 
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Figure 33: Optimization of the ratio and amount of antibodies on PLGA microparticles to function as aAPC. 
Thymidine incorporation assays showing that a ratio of 2:1 (anti-CD3:anti-CD28) and 4 µg of anti-CD3 works the 
best at stimulating T cell proliferation. 
 
 
 
Figure 34: Antibody labeled microparticles remain functional following degradation in saline. 
CFSE dilution assay measuring  the ability of aAPC to stimulate T cell proliferation following incubation in saline 
(simulating conditions for degradation). 
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One of the most common concerns with a procedure that involves covalent coupling of 
antibodies to the surface of degradable microparticles is that the antibodies would be de-coupled 
rapidly as the microparticle degrades. However, it is well established that PLGA microparticles 
degrade from the inside-out (bulk degradation) [223], and hence we presumed that the antibodies 
would not be detached in a short timeframe. Indeed, we observe that the covalently coupled 
antibodies remain functionally active on the surface of microparticles even after incubating the 
particles in saline at 37°C for 3 and 6 days (Figure 34).In conclusion, our data suggests that 
PLGA microparticles labeled with anti-CD3 and anti-CD28 can successfully mimic DC function 
of naïve T cell activation. 
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APPENDIX C  
FABRICATING POROUS PARTICLES 
C.1 INTRODUCTION 
Degradable polymeric microparticles can be classified based on their surface architecture as non-
porous (solid) or porous.  Porous microparticles are of tremendous interest to controlled release 
engineers and pharmaceutical scientist for two reasons: (i) they have low aerodynamic diameters 
that allow for their use in pulmonary delivery applications [224], and (ii) they allow for alteration 
of release kinetics (by changing the porosity of the particle) from a drug-loaded microparticle 
without changing other physical parameters of the microparticle (such as polymer molecular 
weight or geometric diameter of the particle) [225]. 
Industrially, porous microparticles are commonly fabricated using the spray drying 
method. However, the spray drying procedure has many drawbacks such as, loss of structural 
integrity of proteins due to the high temperatures required to produce spray dried particles [226], 
low total yields of microparticles [227-228], and the presence of residual moisture content 
leading to protein instability [229]. An alternative to spray drying is the use of an 
emulsion/evaporation technique in the presence of osmotic gradients to fabricate microparticles 
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[224-225, 230-231]. Thorough characterization of the conditions required to fabricate 
microparticles of different porosities using the latter method have not yet been performed.  
In this study we present descriptive techniques and a few conditions required for the 
fabrication of porous microparticles. 
C.2 MATERIALS AND METHODS: 
C.2.1 Materials 
Poly lactic-co-glycolic acid (PLGA, RG502 and RG502H) as well as Poly lactic acid (PLA) was 
ordered from Boehringer Ingelheim Chemicals, Inc. Polyvinylalcohol (PVA, MW 25,000) was 
purchased from Polysciences, Inc. 
C.2.2 Preparation of Microparticles 
Porous microparticles were prepared using the emulsion/evaporation technique [224-225]. 
Briefly, an aqueous phase (200 µl) consisting of varying sodium chloride concentrations was 
added to 4 ml of dichloromethane (DCM) containing 200 mg of polymer. This mixture was 
sonicated 10 seconds (25% amplitude, Silverson L4RT-A), to create the primary emulsion (water 
in oil). The primary emulsion was then mixed with 60ml of 2% w/v PVA, and homogenized 
(Vibra-Cell Ultrasonic Processor) for 1 minute at 2,500rpm, creating the second emulsion (oil in 
water). The resulting solution was combined with 80ml of 1% w/v PVA and allowed to stir for 3 
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hours at room temperature to allow for DCM to evaporate. Microparticles were then washed 
using de-ionized water (x4), and lyophilized for 48 hours. The particles were stored at -20 C. 
C.2.3 Particle characteristics 
Volume impedance measurements on a Beckman Coulter Multisizer III, were used to determine 
the particle size distribution. Surface characteristics and particle integrity were assessed using 
scanning electron microscopy (JSM6330F). 
C.2.4 Surface Area and Density 
Surface area measurements were obtained with the use of nitrogen utilized BET (Quantachrome 
NOVA 2000 series) surface analyzer. Density measurements were obtained using an 
Ultrapycnometer.  
C.3 RESULTS AND DISCUSSION  
In this study, we observe that increasing sodium chloride in the primary emulsion resulted in 
fabrication of particles with increasing porosity (Figure 35). A possible explanation for the 
occurrence of these pores could be the osmotic imbalance between the inner emulsion and the 
outer aqueous phase, which leads a rapid influx of water causing the emulsions to swell and burst 
(thereby leaving an open pore). Additionally, the formation of pores is not dependent on the type 
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of excipient (ionic vs. non-ionic) used in the inner emulsion as both sodium chloride and 
mannitol loaded particles show porous surfaces (Figure 36). 
 
 
 
Figure 35: Scanning electron micrographs of microparticles prepared with varying amounts of 
NaCl in the primary emulsion. 
0 mM 5 mM 15 mM
30 mM 50 mM 150 mM
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Figure 36: Scanning electron micrographs of microparticles prepared with equi-osmolal amounts of NaCl 
and mannitol. 
Osmolarity measurements showed that 15mM NaCl and ~27.5 mM mannitol solutions have similar osmolarity 
(presumably because NaCl freely dissociates to Na+ and Cl- ions). Microparticles prepared with these 
concentrations of excipients have similar surface porosity as observed through these micrographs. 
 
Interestingly, it was observed that particle porosity also depended on the polymer 
characteristics. Microparticles prepared under different osmotic gradients using the RG502H 
polymer (containing a free carboxy group at the polymer chain termini – acid number 6 mg 
KOH/g) were porous, while particles made with the RG502 polymer (containing an alkyl ester 
group at the polymer chain termini – acid number 1 mg KOH/g) were non-porous (Figure 37). 
Similar differences were observed when using PLA and PCL (more hydrophobic end groups 
15 mM NaCl 27.5 mM mannitol
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when compared to PLA) to fabricate microparticles (Figure 37). Such dramatic differences in the 
porosity of the particle surface could be due to differences in the hydrophilicity of polymer end-
groups used. Presumably, microparticles with relatively hydrophilic surfaces (determined by the 
nature of polymer end-groups) allow for faster diffusion of water through the polymer to the 
inner emulsion, which leads to swelling and bursting of the inner emulsion and subsequent pore 
formation. 
 
 
 
Figure 37: Scanning electron micrographs of microparticles prepared using different polymers. 
Microparticle surface hydrophobicity (dictated by the nature of polymer end groups) may have a role to play in 
establishing particle porosity, as polymers with relatively hydrophilic end-groups (RG502H PLGA and PLA) form 
pores when osmotic gradients are created between the inner emulsion and outside, while polymers with relatively 
hydrophobic end-groups (RG502 PLGA, PCL) do not form pores. 
 
Further, preliminary densities as well as surface area measurements were obtained from 
the porous particles to determine if any of them could potentially be used for pulmonary delivery 
of therapeutics (Table 2). As expected, we observe that the surface area increases while the 
density decreases, with increasing porosity of microparticles. The suggested density value 
RG502H RG502 PCL PLA
1 mM
100 mM
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(which determines the aerodynamic diameter) required for deep lung deposition and pulmonary 
delivery of therapeutics is 0.4 g/cc [232]. This suggests that 50mM microparticles, which have a 
density of 0.25 g/cc, would be ideal for pulmonary delivery. 
 
 
Table 2: Surface area and density measurements for porous microparticles prepared under different 
conditions. 
All measurements are based on n = 1. Surface area was determined using a Quantachrome surface area analyzed, 
Avg. dia. using a Beckman Coulter Counter, and the Avg. density using an ultrapycometer 
 
 
 
NaCl Conc. (mM) Polymer
Surface Area 
(m2/g)
Average 
Diameter (μm)
Average Density 
(g/cc)
1 502H 18.0 11.5 ± 4.8 ND
5 502H 69.8 11.5 ± 4.1 ND
15 502H 79.4 15.2 ± 7.4 ND
30 502H 109 16.5 ± 6.9 1.12
50 502H 246 18.8 ± 9.7 0.25
1 502 30.5 10.3 ± 3.8 ND
100 502 27.3 12.9 ± 4.6 ND
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Finally, to determine if release kinetics can be altered by making microparticles porous, 
we encapsulated a chemokine, CCL22, in non-porous or porous particles. Release of the 
chemokine from these particle sets was measured over 4 weeks using a CCL22-specific ELISA. 
We observe that the porous particles release greater amounts of CCL22 continuously over the 4 
week period (Figure 38), while the non-porous particles remain in the lag phase of release [159-
160]. 
 
 
 
 
Figure 38: CCL22MP release kinetics. 
Release kinetics of non-porous and porous CCL22 microparticles as measured in PBS. 
Porous CCL22MP release is the same as the one depicted in Figure 9. 
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